{
    "fullText": "2048 The chemistry of isoindole natural productsKlaus Speck and Thomas Magauer*Review Open AccessAddress: Department of Chemistry, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen,Butenandtstra\u00dfe 5\u201313, 81377 M\u00fcnchen, GermanyEmail: Thomas Magauer* -thomas.magauer@lmu.de* Corresponding authorKeywords: isoindole; isoindoline; isoindolinone; isoindolone; natural productsBeilstein J. Org. Chem. 2013, 9, 2048\u20132078.doi:10.3762/bjoc.9.243 Received: 12 July 2013Accepted: 18 September 2013Published: 10 October 2013This article is part of the Thematic Series \"Natural products in synthesisand biosynthesis\" and is dedicated to Prof. Dr. Wolfgang Steglich on theoccasion of his 80th birthday.Guest Editor: J. S. Dickschat\u00a9 2013 Speck and Magauer; licensee Beilstein-Institut.License and terms: see end of document.Abstract This review highlights the chemical and biological aspects of natural products containing an oxidized or reduced isoindole skeleton.This motif is found in its intact or modified form in indolocarbazoles, macrocyclic polyketides (cytochalasan alkaloids), theaporhoeadane alkaloids, meroterpenoids from Stachybotrys species and anthraquinone-type alkaloids. Concerning their biologicalactivity, molecular structure and synthesis, we have limited this review to the most inspiring examples. Within different congeners,we have selected a few members and discussed the synthetic routes in more detail. The putative biosynthetic pathways of thepresented isoindole alkaloids are described as well.Introduction Isoindole (2H-isoindole, 1), known since more than a century,consists of a fused benzopyrrole ring system and constitutes theregioisomer of the abundant 1H-indole heterocycle. The fullyreduced member of the isoindole family is termed isoindoline(2,3-dihydro-1H-isoindole, 2). Formal oxidation to the 10\u03c0-system leads to isoindole (1), which is usually only stable whenthe labile ortho-quinoid structure is embedded in a \u03c0-system [1].Incorporation of additional oxygen gives the isoindolinone (1,3-dihydro-2H-isoindole-1-one, 3) and phthalimide (1,3-dihydro-2H-isoindole-1,3-dione, 4) substitution pattern.The isoindole structure has attracted scientists for decades andcan be found in several natural and pharmaceutical compounds[2,3]. A number of structures were explored over the years andpromising drug conjugates such as 5\u201311 could be developed(Figure 1).Compared to the synthesis of indoles, where a number ofnamed-reactions have been reported, only conventionalmethods are used for the related isoindole motif. For theconstruction of this rare skeleton inter-and intramolecularDiels\u2013Alder reactions are one of the most powerful methods.This was also exemplified by medicinal chemists fromAstraZeneca in the manufacturing route to an mGluR2 positiveallosteric modulator [4]. In 2012, a programmable enantiose-lective one-pot synthesis of isoindolines was reported Beilstein J. Org. Chem. 2013, 9, 2048\u20132078.2049 Figure 1: a) Structural features and b) selected examples of non-natural Beilstein J. Org. Chem. 2013, 9, 2048\u20132078.2050 Scheme 2: Staining amines with 1,4-diketone 19 (R = Beilstein J. Org. Chem. 2013, 9, 2048\u20132078.2051 Figure 2: Representative members of the indolocarbazole alkaloid Beilstein J. Org. Chem. 2013, 9, 2048\u20132078.2052 Scheme 3: Biosynthesis of staurosporine Beilstein J. Org. Chem. 2013, 9, 2048\u20132078.2053 Scheme 4: Wood\u2019s synthesis of K-252a via the common intermediate Beilstein J. Org. Chem. 2013, 9, 2048\u20132078.2054 ketone 48 was reduced and regioselectively methylated at theC3\u2019 position. Cleavage of the protecting group gave 49,whereas 50 was obtained after dehydration using Martin\u2019ssulfurane, dihydroxylation and a final deprotection step.Scheme 5: Synthesis of 26, 27, 49 and 50 diverging from the commonintermediate 48.Macrocyclic polyketides: The first cytochalasan alkaloids,cytochalasin A (51) and B (52), originally named phomins [39],were isolated in 1966 [39-42]. Since then, the number of naturalproducts belonging to this family has increased to over 80.Some representative members are depicted in Figure 5 [43].Cyctochalasan alkaloids display a wide range of biologicalproperties, such as cytotoxic, antimicrobial, antiviral and phyto-toxic activities and were reviewed in detail by Hertweck in2010 [44]. Structurally, they consist of one amino acid and ahighly substituted hydroisoindolone moiety fused to a macro-cyclic ring (ring size 9\u201314). In certain cases, the ring system canbe oxidized to an unusual cyclic carbonate as observed forcytochalasin E (53). Depending on the amino acid incorporatedin the isoindolone moiety, the cytochalasans can be furthersubdivided into cytochalasins [41] (phenylalanine), chaetoglo-bosins [45,46] (tryptophan), aspochalasins [47] (leucine),pyrichalasins [48] (tyrosine) or alachalasins [49,50] (alanine).The biosynthesis of cytochalasans was established on the basisof various isotope labeling experiments using cytochalasin B(52) as a model system [51-55]. It was hypothesized that thecarbon backbone, which is connected to an amino acid, mostlikely originates from a polyketide synthase (PKS)/nonribo-somal peptide synthetase (NRPS) hybrid machinery [56]. Thediscovery of a gene locus for a PKS-NRPS synthetase of thechaetoglobosin producing fungus Penicillium expansum led to amore sophisticated biosynthetic insight of chaetoglobosin A(57) (Scheme 6). The stepwise assembly of the nonaketide 61 isrealized from activated tryptophan (36), one acetyl-CoA (59)starter and eight malonyl-CoA extender (60) units. Theremaining methyl groups are believed to be installed byS-adenosyl methionine (SAM). An intramolecular Aldol con-densation generates the pyrrolinone 62, which reacts via an[4 + 2]-cycloaddition to prochaetoglobosin I (63) [56].Recently, gene disruption studies of Chaetomium globosumrevealed the enzymes involved in the final oxidative transfor-mations leading to chaetoglobosin A (57) [57].The diverse biological activities and unique molecular architec-ture of the cytochalasan alkaloids have made them a famoussynthetic target. Total syntheses of several members of thecytochalasans were reported, which were reviewed by Hertweckand Br\u00e4se [44,58]. In line with the focus on the construction ofthe isoindole component, one can identify the Diels\u2013Alder reac-tion as the most popular strategy. A linear, biomimetic syn-thesis using a late stage intramolecular Diels\u2013Alder reactionwas implemented in the Stork synthesis of cytochalasin B (52)[59] and the Thomas synthesis of cytochalasin H, D, G and O[60-63]. An intermolecular reaction was reported for the syn-thesis of aspochalasin B (58) by Trost and Vedejs [64-67]. Thesynthesis of cytochalasin D (70) by Thomas is outlined inScheme 7. The intermediate 67, which contains all of the carbonatoms of the natural product, was synthesized in eight stepsstarting from the advanced building blocks 64, 65 and 66.Selective deprotonation and trapping the so-formed enolate withphenylselenyl chloride gave an intermediate selenide. Beilstein J. Org. Chem. 2013, 9, 2048\u20132078.2055 Figure 5: Selected members of the cytochalasan alkaloid Beilstein J. Org. Chem. 2013, 9, 2048\u20132078.2056 Scheme 7: Synthesis of cytochalasin D (70) by Thomas Beilstein J. Org. Chem. 2013, 9, 2048\u20132078.2057 Scheme 9: Synthesis of aldehyde 85 (R = Beilstein J. Org. Chem. 2013, 9, 2048\u20132078.2058 Scheme 10: Synthesis of (+)-aspergillin PZ (79) by Tanis.via intermediate 84 to give the cis-aldehyde 85. However, onlythe diastereomeric trans-aldehyde 83 was isolated in moderateyields from the reaction mixture. The authors concluded that acompeting 2-oxonia-[3,3]-sigmatropic aldol pathway via 82aand 82b might be operative for this system. The stereochemicaloutcome could be attributed to the sterically less demandingtransition state 82b. The epimerization of 83 to 85 proceededvia an intermediate lactone and extended the route by sevensteps. After having secured the cis-epimer 85, the diene moiety wasintroduced in four steps to give aldehyde 86, which was reactedwith the lithium enolate of lactam 87 to furnish the aldol adduct88 (Scheme 10). Oxidation of the secondary alcohol to thecorresponding ketone and selective selenation with phenylse-lenyl chloride gave 89. Following the reported sequence for thesynthesis of cytochalasin D (70), namely oxidation of theselenide to the selenoxide, elimination and intramolecularDiels\u2013Alder reaction, isoindolinone 90 could be obtained inmoderate yield. Removal of the protecting groups then yieldedaspergillin PZ (91).Though having established a rather long and low yielding syn-thesis, ample quantities could be obtained for a preliminaryevaluation of the biological activity of 79. In a first screenagainst A2058 melanoma and DU145 prostate cancer cell lines,79 showed to be inactive [73].Isoindolinones derived from isoquinoline alkaloids: Theaporhoeadane alkaloids, a term designated by Shamma [75], areabundantly found in South American members of the botanicalfamily of Berberis (Berberidaceae). Along with the everpresent isoquinoline berberine (92), the isoindole-containingbenzazepines chilenine (93) [76], lennoxamine (94) [77] andchilenamine (95) [78], the isoquinoline nuevamine (96) [77]and the benzazocine magallanesine (97) [79] were isolated fromdifferent Berberidaceae species (Figure 6).Figure 6: Representative Berberis alkaloids.Chilenine (93) was the first isoindolobenzazepine alkaloidisolated from Berberis empetrifolia in 1982. The biogenesisproceeds most likely via a Pictet\u2013Spengler reaction of dopamine(99) with 4-hydroxyphenylacetaldehyde (100), both Beilstein J. Org. Chem. 2013, 9, 2048\u20132078.2059 Scheme 11: Proposed biosynthetic pathway to chilenine (93).from L-tyrosine (98) (Scheme 11). After oxidation andO-methylation, which is carried out by S-adenosylmethionine(SAM), (S)-reticuline (101) is obtained. Oxidation of theN-methyl group to the iminium ion and cyclization gives thetetracyclic carbon skeleton, which upon further methylation andoxidation furnishes berberine (92) [80]. Prechilenine (102),itself isolated as its O-methyl ether is formed via oxidation [78].A base-catalyzed semipinacol-type rearrangement yields 93[76]. Chilenine (93) can be further transformed to the [4.4.0]-tricycle lennoxamine (94) and the [5.3.0]-ring system chile-namine (95) [77-79]. Other members such as nuevamine (96)and magallanesine (97) contain the corresponding [4.3.0] and[6.3.0]-scaffold. Since their first isolation in the 80\u2019s of the last century, amyriad of syntheses of these small, sometimes highly function-alized and mainly biological inactive alkaloids have beendescribed in the literature. Most of this work is summarized inan excellent review by Leonard [81]. We confine this section tothe syntheses of magallanesine (97) by Danishefsky and Kuri-hara, which were also mentioned by Evans and Bentley [82,83].Magallanesine (97), which was isolated in 1985 from Berberisdarwinii, a plant native to southern Chile and Argentina, is thefirst known isoindolobenzazocine alkaloid. The seminal totalsynthesis of 97 was achieved in the group of Danishefsky(Scheme 12) using a dimethylformamide acetal-mediatedcyclodehydration of 105. The isoindole unit of 105 wasprepared from the condensation of 103 and 104. Oxygen\u2013sulfurScheme 12: Synthesis of magallanesine (97) by Danishefsky Beilstein J. Org. Chem. 2013, 9, 2048\u20132078.2060 Scheme 13: Kurihara\u2019s synthesis of magallanesine (85).exchange provided the thiophthalimide 105, which could beconverted to magallanesine (97) via an intramolecular aldolcondensation in one step [84].In 1996, Kurihara (Scheme 13) reported a [1,2]-Meisenheimerrearrangement followed by an intramolecular Heck cyclizationto elaborate the isoindolobenzazocine moiety [85]. The syn-thesis commenced with the preparation of ester 106 from piper-onal according to a known procedure [86]. A four-step sequenceyielded azetidine 107. After oxidation with hydrogen peroxide,the resulting N-oxide cleanly underwent a [1,2]-Meisenheimerrearrangement upon heating in tetrahydrofuran. The so-formedazocine 108 was converted to amine 109 by hydrogenolysis ofthe N\u2013O bond. Amide formation with acid chloride 110 gave111, which upon sequential oxidation yielded enaminone 112.Finally, the isoindolinone moiety was generated via anintramolecular Heck reaction using tetrakis(triphenylphos-phine)palladium(0) and thallium acetate, to give magallanesine(97) in excellent yield [85].Aporphine alkaloids: The aristolactam alkaloids are classifiedas members of the aporphine alkaloid family and contain a char-acteristic phenanthrene lactam core. Aristolactams (113\u2013116)along with aristolochic acids (117,118) and 4,5-dioxoapor-phines (119,120) were mainly isolated from Aristolochiaceaebut can also be found in several other plant species (Table 1)[87-92]. Several comprehensive overviews of various aristolac-tams were published by Shamma, Parmar and Bentley [87,92-95]. The co-occurrence of aristolactams, aristolochic acids and 4,5-dioxoaporphines led to the assumption of a close biogeneticrelationship between these three classes [87,96]. The biosyn-thesis of aristolochic acid I (117) was elucidated via labelingexperiments and is depicted in Scheme 14 [97-100]. First, twomolecules of the amino acid L-tyrosine (98) are transformed to(R)-orientaline (121) in a similar fashion as described for thebiogenesis of (S)-reticuline (101) (compare Scheme 11). Ade-aromatizing spirocyclization of 121 leads to (R)-orientali-none (122), which, after reduction of the ketone to the second-ary alcohol 123, undergoes a [1,2]-alkyl migration withconcomitant loss of water. Re-aromatization and dioxolane for-mation gives stephanine (124). It is hypothesized that direct oxi-dation of 124 forms 4,5-dioxoaporphine 125, which uponbenzilic acid rearrangement, N-methyl cleavage and decarboxy-lation provides aristolactam I (113) [96]. Additional oxidationof the amide function furnishes aristolochic acid I (117).The aristolactams and aristolochic acids have a broad spectrumof biologically interesting properties. Although both can beisolated from the same plants, their biological activity is highlyvariable. Herbal drugs containing aristolochic acids Beilstein J. Org. Chem. 2013, 9, 2048\u20132078.2061 Table 1: Selected members of the aporphine alkaloid Beilstein J. Org. Chem. 2013, 9, 2048\u20132078.2062 Scheme 16: Snieckus\u2019 synthesis of piperolactam C (131).Scheme 15: DNA lesion caused by aristolochic acid I (117) [102].Interestingly, aristolactams are not mutagenic themselves butshow immunosuppressant [104], antiplatelet [105], antimy-cobacterial [106], neuroprotective [107] activities and are excel-lent inhibitors of cyclin-dependent kinases (CDKs) with IC50values in the nanomolar range [108,109]. CDKs are regulatoryproteins, which play an important role in the cell cycle and areconsidered to be a potential target for anticancer treatment. Thismakes the aristolactams promising lead components for furtherdrug discovery [108]. The similarity of the aromatic moiety ofaristolactams and staurosporines, which are also known to bepotent kinase inhibitors could explain the observed inhibition ofcyclin-dependent kinases [109]. Over the past years, consider-able synthetic efforts have been dedicated to the aristolactamsand the development of non-natural analogues.Pioneering work was carried out in the groups of Castedo [110]and Couture [111,112]. A beautiful application of a directedortho-metalation (DoM) strategy was reported in the synthesisScheme 17: Synthesis of aristolactam BII (104).of piperolactam C (131) by Snieckus (Scheme 16) [113]. Treat-ment of 129 with base afforded aminophenanthrene 130 via aremote lateral metalation\u2013cyclization sequence. Metalation of130 with excess n-butyllithium followed by carbonation thenyielded piperolactam C (131).In 2008, Heo and coworkers reported the synthesis of severalaristolactams employing a one-pot cross-coupling/aldol conden-sation cascade reaction (Scheme 17) [91]. The synthesiscommenced with the preparation of the isoindolinone buildingblock 134. Friedel\u2013Crafts acetylation of 132, followed by aLieben haloform degradation gave the corresponding acid,which after methylation yielded 133. Bromination and lactamformation afforded isoindolinone 134. The following one-potSuzuki\u2013Miyaura/aldol condensation of 134 with boronic acid135 was carried out at 150 \u00b0C in a microwave reactor and Beilstein J. Org. Chem. 2013, 9, 2048\u20132078.2063 Figure 7: Representative cularine Beilstein J. Org. Chem. 2013, 9, 2048\u20132078.2064 Scheme 19: The syntheses of 136 and 137 reported by Castedo and Suau.regioisomeric iso-cularine sarcocapnidine (141) could serve asbranching points for the synthesis of further cularine deriva-tives. Sequential oxidations of 141, similar to the biosynthesisof the aristolactams (Scheme 14), yields yagonine (146), whichcould be converted to aristoyagonine (136) via a benzilic acid-type rearrangement [121].The first syntheses of aristoyagonine (136) were reported byCastedo and Suau (Scheme 19) [121,122,125-127]. The ap-proach carried out by Castedo relied on 3-hydroxysarcocapnine(147), which could either be isolated from natural sources orprepared via an Ullmann coupling of a 1-(2-bromobenzyl)-8-hydroxyisoquinoline derivative [121,125]. Oxidation of 147with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) gavethe dioxocularine yagonine (146). The bioinspired, base-medi-ated transformation of 146 to 136 obviously proceeds via abenzilic acid rearrangement\u2013oxidation sequence.In 1996, the group of Suau accessed aristocularine 137 alongwith 149 in one step from acetamide 148. In the presence ofoxalyl chloride and the Lewis acid tin(IV) chloride, a tandemcyclization (Bischler\u2013Napieralski/Friedel\u2013Crafts acylation reac-tion) was triggered to directly give 137 and 149 [122,127].In 2006, another approach to aristoyagonine (136) was reportedby the group of Couture (Scheme 20) [128]. For the preparationof 136, their previously developed procedures for the synthesesScheme 20: Synthesis of 136 by Beilstein J. Org. Chem. 2013, 9, 2048\u20132078.2065 Figure 8: Representative isoindolinone Beilstein J. Org. Chem. 2013, 9, 2048\u20132078.2066 Scheme 21: Postulated biosynthetic pathway for the formation of 156 (adopted from George) [143].togenic properties (161) [134]. So far, only a few total syntheseswere accomplished and the exact biosynthetic pathways areunknown. The sesquiterpenoid stachyflin (156) was first isolated from thefungus Stachybotrys sp. RF-7260 by Shionogi & Co., Ltd.,Japan, in 1997 [130] and shows outstanding antiviral activityagainst the influenza A subtype H1N1 (IC50 = 3 nM), outper-forming current drugs such as amantadine and zanamivir [141].The putative biosynthesis of 156, which contains a pentacyclicring system with a cis-fused decalin is depicted in Scheme 21.Farnesyl pyrophosphate (167), which originates from theterpenoid pathway through the condensation of dimethylallylpyrophosphate (DMAPP, 165) with two units of isopentylpyrophosphate (IPP, 166), and orsellinic acid (168), which isderived from a fungal iterative type I polyketide pathway [142],are connected to give 169. This substrate is already poised for apolyene cyclization cascade, which only has to be triggered viaactivation of the epoxide. After the decalin moiety has formed,two sigmatropic, stereospecific [1,2]-shifts of intermediate 170provide the tertiary carbocation 171, which could be trapped bythe phenolic alcohol to give stachyflin (156) [143].In 2011, the first enantioselective total synthesis of (+)-stachyflin (156) via a Lewis acid induced domino epoxide-opening/rearrangement/cyclization cascade was accomplishedby the group of Katoh (Scheme 22) [144]. The synthesiscommenced with the conversion of dimethyl 2,6-dihydroxy-terephthalate (172) to nitrile 173 within five consecutive steps.Hydrogenation and lactam formation of 173 gave isoindolinone174, which was converted to bromide 175. Reductive alkyl-ation of the protected Wieland\u2013Miescher ketone 176 with bro-mide 175 using Birch conditions gave 177 as a single diastereo-isomer. Epoxide 178 could be prepared in seven steps from 177,but was obtained as a mixture of inseparable diastereoisomers.The Lewis acid induced key step, a domino epoxide-opening/rearrangement/cyclization cascade, most likely proceeded in astepwise manner via intermediate 179. Activation of theepoxide with boron trifluoride etherate induces the plannedsigmatropic [1,2]-methyl and [1,2]-hydride shifts to generatethe tertiary carbocation at the ring junction. This is then trappedby the phenol to give the pentacyclic compounds 180a and180b. The former diastereoisomer could be converted to 180bvia inversion of the secondary alcohol. Cleavage of the methylether and the 3,4-dimethoxybenzyl (3,4DMB) group of 180b ledto (+)-stachyflin (156). The synthesis proceeded in 25 stepswith an overall yield of 2.6%.Another novel class of isoindolinone-containing natural prod-ucts, categorized as spirodihydrobenzofuranlactams or stachy-botrylactams (157, 181, 182), was isolated from differentStachybotrys species by Jarvis and Roggo between 1995 and1996 (Figure 9) [131,132]. These compounds are antagonists ofendothelin and display strong immunosuppressant Beilstein J. Org. Chem. 2013, 9, 2048\u20132078.2067 Scheme 22: Synthesis of stachyflin (156) by Katoh [144].Figure 9: Selected examples of Beilstein J. Org. Chem. 2013, 9, 2048\u20132078.2068 Scheme 23: Synthesis of stachybotrylactam I (157).The pseudosymmetric dimer stachybocin A (182), which wasisolated by Ogawa in 1995 [145], constitutes the most potentrepresentative [132]. Oxidation of the isoindolinone unit of 157gives the relatively scarce phthalimide motif, which is presentin stachybotrylactam V (181).To date, only one enantioselective total synthesis of spirodihy-drobenzofuranlactam I 157 has been published (Scheme 23)[146]. The synthesis carried out by the group of Guocommenced with trans-decalone 183, which was derived fromthe Wieland\u2013Miescher ketone. For the conversion of 183 to the\u03b1,\u03b2-unsaturated aldehyde 184 six steps were necessary.Halogen\u2013metal exchange of 185 with n-butyllithium followedby the addition of 184 gave the carbinol 186 in good yield.Removal of the benzyl groups, cleavage of the tert-butyl groupwith concomitant formation of the methoxy ester (COOt-Bu \u2192COOMe), and global deprotection gave 187. Acid-catalyzed(Amberlyst 15) spiroannulation afforded a 1.7:1 mixture of thebenzofuran and the benzopyran (90% overall conversion). Forthe installation of the isoindolinone, a seven-step sequencesimilar to the one described for stachyflin (156) was usedScheme 24: Synthesis of pestalachloride A (193) by Schmalz.(Scheme 23). The arene appendage was desymmetrized viamonobromination and cross coupling with copper cyanideprovided a nitrile. Hydrogenation and lactam formation underbasic conditions completed the synthesis of stachybotrylactam I(157). Chlorinated isoindolinone alkaloids: Pestalachloride A (193)was isolated from the plant endophytic fungus Pestalotiopsisadusta as a racemate and displays potent antifungal activitiesagainst Fusarium culmorum (IC50 = 0.89 \u00b5M) [147]. Pestalone(192), a natural product and synthetic precursor of 193 showsstrong antibiotic activity against methicillin-resistant Staphylo-coccus aureus (MRSA, MIC = 84 nM) and vancomycin-resis-tant Enterococcus (VRE, MIC = 178 nM) [148]. The structuralsimilarity between pestalachloride A (193) and pestalone (192),which both contain the same prenylated polyketide core imply adirect biosynthetic relationship [147]. The reaction of 192 withan equivalent of ammonia gives a cyclic iminohemiaminal,which first tautomerizes to the hydroxy isoindole and then tothe isoindolinone 193. This biosynthetic transformation wasalso used in the total synthesis of 193 by Schmalz (Scheme Beilstein J. Org. Chem. 2013, 9, 2048\u20132078.2069 Scheme 25: Proposed mechanism for the BF3-catalyzed metal-free carbonyl\u2013olefin metathesis [149].[149]. Reaction of lithiated 188 (three steps from commerciallyavailable 5-methylresorcinol) with the aldehyde 189 (doublebromination of 3,5-dimethoxybenzaldehyde) gave the racemicalcohol 190.Oxidation to the benzophenone, installation of the prenyl sidechain and introduction of the formyl group was accomplishedwithin five steps to give 191a (Scheme 25). The envisioneddeprotection of 191a using Lewis acidic conditions led to anunexpected and unprecedented metal-free carbonyl\u2013olefinmetathesis. Coordination of boron trifluoride etherate to 191apromotes the formation of the tertiary carbenium ion 194, whichisomerizes via the oxetane intermediate 195 to the benzyliccation 196. Expulsion of acetone then yields indene 197 inexcellent yield. Avoiding this side reaction could only beachieved by exchanging the methyl ether protecting group for amore labile methoxymethyl ether at the benzophenone stage.The following prenylation and formylation proceeded smoothlyunder the same conditions to give 191b (Scheme 24). Cleavageof the MOM ethers afforded pestalone (192), which could beconverted into 193 in a single step by treatment of 192 withammonia in aqueous ammonium chloride solution (pH 8).Muironolide A (204) was isolated by Molinski from the marinesponge Phorbas sp. in 2009 [150]. The molecular framework ofthis unique natural product has a hexahydro-1H-isoindolinone-triketide, a trans-2-chlorocyclopropane and a trichlorocarbinolester. A first biological evaluation showed that 204 displaysantifungal activity. However, only 90 \u00b5g could be isolated andfurther biological screening was not possible [151]. Severalsponge-derived macrolides have proven to be effective cyto-toxic agents [152,153] and one could speculate that muirono-lide A (204) shares this potential. A first attempt to access 204in the laboratory was reported by Molinski shortly after theisolation (Scheme 26) [151]. Coupling of the dienophileprecursor 198 with sorbic acid (199) gave a tertiary amide,which was converted to 200 via a reduction\u2013oxidationsequence. The asymmetric intramolecular Diels\u2013Alder reactionwas then catalyzed by Kristensens\u2019 catalyst (201) to give 202. Abase-promoted epimerization of the aldehyde and aHorner\u2013Wadsworth\u2013Emmons reaction furnished 203, the mostadvanced intermediate reported so far.Just recently, the group of Zakarian reported another approachto the fully elaborated isoindolinone core of 204 [154].Chlorizidine A (208) (Scheme 27), a cytotoxic metabolite froma marine Streptomyces species shows an unprecedented5H-pyrrolo[2,1-a]isoindolinone ring system, which is connectedto a dichlorinated pyrrolizine [155]. Chlorizidine A (208) andits semisynthetic derivatives display significant cytotoxic activi-ties against various human cancer cell lines. The IC50 value of208 against the colon cancer cell line HCT-116 was determinedto be in the micromolar range (3.2\u20134.9 \u03bcM) [155]. A firstbiosynthesis was postulated on the basis of the structural simi-larity between 208 and marinopyrrole A, another secondarymetabolite derived from a marine Streptomyces species [156].The common biosynthetic precursor 206 stems from a Beilstein J. Org. Chem. 2013, 9, 2048\u20132078.2070 Scheme 26: Preparation of the isoindoline core of muironolide A (204).nonribosomal peptide synthetase (NRPS)/polyketide synthase(PKS) pathway. The amino acid proline is first oxidized andchlorinated by an FADH2-dependent halogenase to give 205,which after extension by the polyketide synthase gives thepolyketides 206 and 207, respectively. The intermolecular con-densation of these two components yields chlorizidine A (208)[155]. Anthraquinone-type alkaloids: Lactonamycin (215) andlactonamycin Z (217) were isolated from Streptomycesrishiriensis and Streptomyces anglieri in 1996 and 2003[157,158]. Both compounds are potent antibacterial agentsagainst Gram-positive bacteria, including methicillin-resistantStaphylococcus aureus (MRSA) and vancomycin-resistantScheme 27: Proposed biosynthesis of 208.Enterococcus (VRE) [159]. Beyond that, the modest cytotoxicactivity of 215 and 217 against human cancer cell lines makesthem interesting lead components for drug discovery. The IC50values of 215 for different leukemia cell lines range from0.11\u20130.22 \u00b5M. For 217, an IC50 value of 0.32 \u00b5M againstgastric adenocarcinoma was observed [157,158]. The hexa-cyclic aglycone of 215 and 217, lactonamycinone (214),consists of a densely oxygenated fused hydrofuran\u2013hydrofura-none and a naphta[e]isoindole ring system. The core of lactona-mycin (215) is decorated with the 2-deoxysugar \u03b1-L-rhodino-pyranose (216), whereas \u03b1-L-2,6-dideoxyribopyranose (218) isfound in 217. The structure of the aglycone 214 is related totetracenomycins, a family of tetracyclic aromatic polyketides,which are produced by several Streptomyces species [159].Biosynthetic investigations revealed a striking similarity of thegene cluster responsible for the biogenesis of lactonamycinone(214) to those clusters found in tetracenomycin-producingbacteria. Cloning experiments and incorporation of variouslabeled precursors resulted in a first hypothesis for the biogen-esis of 215 and 217 (Scheme 28) [159]. This led to the assump-tion that the aglycone 214 is assembled from nine acetate unitsand glycine, respectively N-methylglycine derivative, whichcontributes both carbon atoms and the nitrogen to the skeletonof 210 (position 12 and 12a). The latter are uncommon Beilstein J. Org. Chem. 2013, 9, 2048\u20132078.2071 Scheme 28: Model for the biosynthesis of 215 and 217.units in a type II polyketide assembly line [160]. Upon oxida-tive cleavage of the D-ring of the putative tetracenomycin-likeintermediate 210, the aldehyde 211 is reduced to the corres-ponding alcohol 212. Acetalization and introduction of the 1,2-cis-diol moiety furnishes 213. Sequential formation of thelactone and the isoindolinone generates 214. A final glycosyl-ation step leads to lactonamycin (215) and lactonamycin Z(217). The remarkable structure and the promising biological activi-ties have attracted many synthetic groups. Several totalsyntheses of 215 and 217 were reported in recent years [161](and references therein). The group of Danishefsky was the firstto report a diastereoselective synthesis of lactonamycinone(214) employing a Diels\u2013Alder reaction [162,163]. In 2010,Tastuta completed the first total synthesis of lactonamycin (215)by using a sequential conjugate addition, a stereoselectiveglycosylation reaction and a Michael\u2013Dieckmann-type cycliza-tion [164]. The recently published total synthesis of lactona-mycin (215) and lactonamycin Z (217) by Saikawa and Nakatais based on a late-stage glycosylation strategy (Scheme 29).This enables the specific variation of the sugar components andgives access to various lactonamycin derivatives [161].Starting from alcohol 219, the diene precursor 220 could beprepared in seven steps. The following Diels\u2013Alder reactionwith chloroethynylquinone 221, which was synthesizedaccording to a known procedure [165] proceeded in a highlyregioselective manner to give antharaquinone 222. Introductionof the fused hydrofuran\u2013hydrofuranone moiety wasaccomplished via deprotection, palladium-catalyzed cycliza-tion\u2013methoxycarbonylation [166] and an acid-catalyzed lactoneformation to afford 223. For the generation of the isoindolinonevia a Bischler\u2013Napieralski reaction, a chloroacetyl (CA)-protected phenol was essential to avoid competing carbamateformation of the starting material. Upon exposure of 223 tophosphorus pentoxide, the desired isoindolinone 224 wasformed in 75% yield. Deprotection led to lactonamycinone(214), which was the substrate for a ytterbium triflate-catalyzedglycosylation to give 215 and 217, Beilstein J. Org. Chem. 2013, 9, 2048\u20132078.2072 Scheme 29: Synthesis of lactonamycin (215) and lactonamycin Z (217).Miscellaneous: At first glance, the hetisine alkaloids do notshow any structural similarities with the compound classesdescribed before. However, though lacking an \u201cintact\u201d isoin-dole core, one can spot the corresponding perhydro motif. Sincetheir first discovery more than 70 years ago, more than 100different hetisine alkaloids have been isolated from differentspecies of the plants Aconitum and Delphinium, and to a lesserextend from Rumex, Consolida and Spiraea [167,168]. Theseplants have been widely used in traditional herbal medicine andfurther pharmacological studies revealed that hetisine alkaloidsare highly bioactive compounds [167,168]. The diverse spec-trum includes vasodilatoring, anti-arrhythmic, immunomodu-lating and analgesic activities. Hetisines can be classified,according to Wang and Liang, as C20-diterpenoid alkaloids,which belong to the family of atisane alkaloids [167]. Thehetisines comprise a heptacyclic core and are structurally themost complex members derived from the atisine skeleton. Themost prominent representatives, nominine (225) [169,170],kobusine (226) [171,172], pseudokobusine (227) [173,174] andhetisine (228) [174-176] are depicted in Figure 10.The putative biosynthetic pathway for the formation of the heti-sine alkaloids is derived from phytochemical data and basicbiochemical transformations (Scheme 30) [167]. Cyclization ofgeranylgeranyl pyrophosphate (229), involving the ent-copalyldiphosphate synthase, could give ent-copalyl diphosphate (230).After loss of the pyrophosphate group and double cyclization, a1,3-hydride shift and Wagner\u2013Meerwein rearrangement leads tothe naturally occurring ent-atisir-16-ene (231). Oxidativeincorporation of nitrogen, which might be derived from\u03b2-aminoethanol, generates the atisine-type skeleton 232. Oxida-tive C\u2013C-bond formation gives the hetidine core (233) andC\u2013N-bond formation the hetisine skeleton (234).The first total synthesis of a hetisine-type alkaloid was accom-plished by Muratake and Natsume in 2004 [177]. In Beilstein J. Org. Chem. 2013, 9, 2048\u20132078.2073 Figure 10: Hetisine alkaloids 225\u2013228.Scheme 30: Biosynthetic proposal for the formation of the hetisine core [167].seminal work, (\u00b1)-nominine (225) was synthesized within 40steps and 0.15% overall yield. Two years later, a more conciseand efficient access to (\u00b1)-nominine (225), featuring a oxidoiso-quinolinium-1,3-dipolar cycloaddition and a dienamine-Diels\u2013Alder reaction, was accomplished by Gin (Scheme 31)[178]. Coupling of 235 and 236, both synthesized within threesteps from simple starting materials, via a Staudinger\u2013aza-Wittig reaction gave amine 237 as a mixture of four diastereo-isomers. Conversion into 4-oxido-isoquinolinium betaine 238could be achieved by an acid-catalyzed methanol extrusion andisomerization. Betaine 238 served as the substrate for thefollowing 1,3-aza-dipolar cycloaddition. Carrying out the reac-tion at 180 \u00b0C in tetrahydrofuran provided a separable mixtureof pyrrolidine isomers 241 and 242 (1:3.6). The undesiredcycloadduct 242 could be equilibrated to 241 due to the revers-ibility of the reaction. Conversion to the \u03b2,\u03b3-cyclohexenone Beilstein J. Org. Chem. 2013, 9, 2048\u20132078.2074 Scheme 31: Synthesis of nominine (225).was accomplished within 6 consecutive steps. Generation of thedienamine 244 with pyrrolidine in methanol at 60 \u00b0C triggeredan intramolecular Diels\u2013Alder reaction to provide the fullcarbon skeleton 245. The final transformations of the synthesisinvolved a Wittig olefination of the ketone and a diastereoselec-tive allylic oxidation to provide (\u00b1)-nominine (225). In 2008,the same group reported the first total synthesis of (+)-nomi-nine by introducing the desired stereochemical information tothe nitrile 235 [179].Conclusion The outlined syntheses of natural products containing theuncommon isoindole skeleton are still far away from beingideal. Low yielding multistep strategies dominate for morecomplex molecules and often cannot provide the amountsnecessary for further investigations. Several biologically activemembers are still precluded from extensive biological studiesdue to their low abundance in nature. This and the fact, thatmany compounds are underexplored offers plenty opportunitiesfor the development of innovative chemical transformations.The biosynthesis of many isoindole natural products is stilluncertain and has yet to be unraveled. The presented examplescould serve as an inspiration for the development of novel syn-thetic methods, new biosynthetic insights and drug develop-ment. Considerably more discoveries remain to be uncoveredthrough exciting projects.Acknowledgements Support from the Fonds der Chemischen Industrie (Liebig-Stipendium to T.M.) and Prof. Dirk Trauner is gratefullyacknowledged. We thank Prof. Wolfgang Steglich and Dr.David Woodmansee for helpful discussions. We acknowledgethe many scientists whose important discoveries could not beincluded or referenced in this article.References 1. Heugebaert, T. S. A.; Roman, B. I.; Stevens, C. V. Chem. Soc. Rev.2012, 41, 5626\u20135640. doi:10.1039/c2cs35093a2. Subbarayappa, A.; Patoliya, P. U.Indian J. Chem., Sect. B: Org. Chem. Incl. Med. Chem. 2009, 48,545\u2013552. 3. Belliotti, T. R.; Brink, W. A.; Kesten, S. R.; Rubin, J. R.;Wustrow, D. J.; Zoski, K. T.; Whetzel, S. Z.; Corbin, A. E.;Pugsley, T. A.; Heffner, T. G.; Wise, L. D. Bioorg. Med. Chem. Lett.1998, 8, 1499\u20131502. doi:10.1016/S0960-894X(98)00252-24. Ball, M.; Boyd, A.; Churchill, G.; Cuthbert, M.; Drew, M.; Fielding, M.;Ford, G.; Frodsham, L.; Golden, M.; Leslie, K.; Lyons, S.;McKeever-Abbas, B.; Stark, A.; Tomlin, P.; Gottschling, S.; Hajar, A.;Jiang, J.-l.; Lo, J.; Suchozak, B. Org. Process Res. Dev. 2012, 16,741\u2013747. doi:10.1021/op300002f5. Potowski, M.; Sch\u00fcrmann, M.; Preut, H.; Antonchick, A. P.;Waldmann, H. Nat. Chem. Biol. 2012, 8, 428\u2013430.doi:10.1038/nchembio.901 Beilstein J. Org. Chem. 2013, 9, 2048\u20132078.2075 6. Babichev, F. S.; Kovtunenko, V. A.; Tyltin, A. K. Russ. Chem. Rev.1981, 50, 1087\u20131103. doi:10.1070/RC1981v050n11ABEH0027387. Kovtunenko, V. A.; Voitenko, Z. V. Russ. Chem. Rev. 1994, 63,997\u20131018. doi:10.1070/RC1994v063n12ABEH0001318. Couture, A.; Grandclaudon, P.Stud. Cercet. Stiint.: Chim. Ing. Chim., Biotehnol., Ind. Aliment. (Univ. Bacau) 2010, 11, 11\u201344.9. Armoiry, X.; Aulagner, G.; Facon, T. J. Clin. Pharm. Ther. 2008, 33,219\u2013226. doi:10.1111/j.1365-2710.2008.00920.x10. Frincke, J. M.; Faulkner, D. J. J. Am. Chem. Soc. 1982, 104, 265\u2013269.doi:10.1021/ja00365a048 11. Schubert-Zsilavecz, M.; Schramm, H. W. Liebigs Ann. Chem. 1991,973. doi:10.1002/jlac.199119910116812. Yu, C.; Xu, Y.; Jiao, L.; Zhou, J.; Wang, Z.; Hao, E. Chem.\u2013Eur. J.2012, 18, 6437\u20136442. doi:10.1002/chem.20120039813. Maekawa, E.; Suzuki, Y.; Sugiyama, S. Chem. Ber. 1968, 101,847\u2013854. doi:10.1002/cber.1968101031414. Riemschneider, R.; Hennig, K.; Wons, T. Monatsh. Chem. 1987, 118,831\u2013835. doi:10.1007/BF0080923315. M\u00e9dici, R.; de Mar\u00eda, P. D.; Otten, L. G.; Straathof, A. J. J.Adv. Synth. Catal. 2011, 353, 2369\u20132376.doi:10.1002/adsc.201100386 16. Omura, S.; Iwai, Y.; Hirano, A.; Nakagawa, A.; Awaya, J.;Tsuchiya, H.; Takahashi, Y.; Asuma, R. J. Antibiot. 1977, 30,275\u2013282. doi:10.7164/antibiotics.30.27517. Schmidt, A. W.; Reddy, K. R.; Kn\u00f6lker, H.-J. Chem. Rev. 2012, 112,3193\u20133328. doi:10.1021/cr200447s18. Tamaoki, T.; Nomoto, H.; Takahashi, I.; Kato, Y.; Morimoto, M.;Tomita, F. Biochem. Biophys. Res. Commun. 1986, 135, 397\u2013402.doi:10.1016/0006-291X(86)90008-2 19. Prade, L.; Engh, R. A.; Girod, A.; Kinzel, V.; Huber, R.;Bossemeyer, D. Structure 1997, 5, 1627\u20131637.doi:10.1016/S0969-2126(97)00310-9 20. Hatzimichael, E.; Georgiou, G.; Benetatos, L.; Briasoulis, E.Am. J. Blood Res. 2013, 3, 29\u201351.21. Yamashita, Y.; Fujii, N.; Murakata, C.; Ashizawa, T.; Okabe, M.;Nakano, H. Biochemistry 1992, 31, 12069\u201312075.doi:10.1021/bi00163a015 22. Nakano, H.; Omura, S. J. Antibiot. 2009, 62, 17\u201326.doi:10.1038/ja.2008.4 23. Pearce, C. J.; Doyle, T. W.; Forenza, S.; Lam, K. S.; Schroeder, D. R.J. Nat. Prod. 1988, 51, 937\u2013940. doi:10.1021/np50059a02024. Fr\u00f6de, R.; Hinze, C.; Josten, I.; Schmidt, B.; Steffan, B.; Steglich, W.Tetrahedron Lett. 1994, 35, 1689\u20131690.doi:10.1016/0040-4039(94)88320-3 25. Hoshino, T.; Kojima, Y.; Hayashi, T.; Uchiyama, T.; Kaneko, K.Biosci., Biotechnol., Biochem. 1993, 57, 775\u2013781.doi:10.1271/bbb.57.775 26. S\u00e1nchez, C.; Butovich, I. A.; Bra\u00f1a, A. F.; Rohr, J.; M\u00e9ndez, C.;Salas, J. A. Chem. Biol. 2002, 9, 519\u2013531.doi:10.1016/S1074-5521(02)00126-6 27. Onaka, H.; Taniguchi, S.; Igarashi, Y.; Furumai, T. J. Antibiot. 2002,55, 1063\u20131071. doi:10.7164/antibiotics.55.106328. Onaka, H.; Taniguchi, S.; Igarashi, Y.; Furumai, T.Biosci., Biotechnol., Biochem. 2003, 67, 127\u2013138.doi:10.1271/bbb.67.127 29. Howard-Jones, A. R.; Walsh, C. T. J. Am. Chem. Soc. 2006, 128,12289\u201312298. doi:10.1021/ja063898m30. Howard-Jones, A. R.; Walsh, C. T. J. Am. Chem. Soc. 2007, 129,11016\u201311017. doi:10.1021/ja074380131. Sarstedt, B.; Winterfeldt, E. Heterocycles 1983, 20, 469\u2013476.doi:10.3987/R-1983-03-0469 32. Hughes, I.; Nolan, W. P.; Raphael, R. A.J. Chem. Soc., Perkin Trans. 1 1990, 2475\u20132480.doi:10.1039/P19900002475 33. Moody, C. J.; Rahimtoola, K. F. J. Chem. Soc., Chem. Commun.1990, 1667\u20131668. doi:10.1039/C3990000166734. Moody, C. J.; Rahimtoola, K. F.; Porter, B.; Ross, B. C. J. Org. Chem.1992, 57, 2105\u20132114. doi:10.1021/jo00033a03635. Harris, W.; Hill, C. H.; Keech, E.; Malsher, P. Tetrahedron Lett. 1993,34, 8361\u20138364. doi:10.1016/S0040-4039(00)61431-436. Link, J. T.; Raghavan, S.; Danishefsky, S. J. J. Am. Chem. Soc. 1995,117, 552\u2013553. doi:10.1021/ja00106a07237. Wood, J. L.; Stoltz, B. M.; Goodman, S. N. J. Am. Chem. Soc. 1996,118, 10656\u201310657. doi:10.1021/ja962614338. Wood, J. L.; Stoltz, B. M.; Dietrich, H.-J. J. Am. Chem. Soc. 1995,117, 10413\u201310414. doi:10.1021/ja00146a03939. Rothweiler, W.; Tamm, C. Experientia 1966, 22, 750\u2013752.doi:10.1007/BF01901360 40. Rothweiler, W.; Tamm, C. Helv. Chim. Acta 1970, 53, 696\u2013724.doi:10.1002/hlca.19700530404 41. Aldridge, D. C.; Armstrong, J. J.; Speake, R. N.; Turner, W. B.Chem. Commun. 1967, 26\u201327. doi:10.1039/c1967000002642. Aldridge, D. C.; Armstrong, J. J.; Speake, R. N.; Turner, W. B.J. Chem. Soc. C 1967, 1667\u20131676. doi:10.1039/J3967000166743. Zhang, D.; Ge, H.; Xie, D.; Chen, R.; Zou, J.-h.; Tao, X.; Dai, J.Org. Lett. 2013, 15, 1674\u20131677. doi:10.1021/ol400458n44. Scherlach, K.; Boettger, D.; Remme, N.; Hertweck, C. Nat. Prod. Rep.2010, 27, 869\u2013886. doi:10.1039/b903913a45. Sekita, S.; Yoshihira, K.; Natori, S.; Kuwano, H. Chem. Pharm. Bull.1982, 30, 1618\u20131628. doi:10.1248/cpb.30.161846. Sekita, S.; Yoshihira, K.; Natori, S.; Kuwano, H. Chem. Pharm. Bull.1982, 30, 1629\u20131638. doi:10.1248/cpb.30.162947. Zhou, G. X.; Wijeratne, E. M. K.; Bigelow, D.; Pierson, L. S.;VanEtten, H. D.; Gunatilaka, A. A. L. J. Nat. Prod. 2004, 67, 328\u2013332.doi:10.1021/np030353m 48. Nukina, M. Agric. Biol. Chem. 1987, 51, 2625\u20132628.doi:10.1271/bbb1961.51.2625 49. Zhang, Y.; Tian, R.; Liu, S.; Chen, X.; Liu, X.; Che, Y.Bioorg. Med. Chem. 2008, 16, 2627\u20132634.doi:10.1016/j.bmc.2007.11.042 50. Zhang, Y.; Tian, R.; Liu, S.; Chen, X.; Liu, X.; Che, Y.Bioorg. Med. Chem. 2009, 17, 428. doi:10.1016/j.bmc.2007.11.08451. Vederas, J. C.; Graf, W.; David, L.; Tamm, C. Helv. Chim. Acta 1975,58, 1886\u20131898. doi:10.1002/hlca.1975058070452. Vederas, J. C.; Tamm, C. Helv. Chim. Acta 1976, 59, 558\u2013566.doi:10.1002/hlca.19760590221 53. Robert, J.-L.; Tamm, C. Helv. Chim. Acta 1975, 58, 2501\u20132504.doi:10.1002/hlca.19750580830 54. Probst, A.; Tamm, C. Helv. Chim. Acta 1981, 64, 2056\u20132064.doi:10.1002/hlca.19810640710 55. Hadener, A.; Roth, P.; Tamm, C. Z. Naturforsch., C 1989, 44, 19\u201332.56. Sch\u00fcmann, J.; Hertweck, C. J. Am. Chem. Soc. 2007, 129,9564\u20139565. doi:10.1021/ja072884t57. Ishiuchi, K.; Nakazawa, T.; Yagishita, F.; Mino, T.; Noguchi, H.;Hotta, K.; Watanabe, K. J. Am. Chem. Soc. 2013, 135, 7371\u20137377.doi:10.1021/ja402828w 58. Br\u00e4se, S.; Encinas, A.; Keck, J.; Nising, C. F. Chem. Rev. 2009, 109,3903\u20133990. Beilstein J. Org. Chem. 2013, 9, 2048\u20132078.2076 59. Stork, G.; Nakamura, E. J. Am. Chem. Soc. 1983, 105, 5510\u20135512.doi:10.1021/ja00354a072 60. Dyke, H.; Sauter, R.; Steel, P.; Thomas, E. J.J. Chem. Soc., Chem. Commun. 1986, 1447\u20131449.doi:10.1039/C39860001447 61. Thomas, E. J.; Whitehead, J. W. F. J. Chem. Soc., Chem. Commun.1986, 727\u2013728. doi:10.1039/C3986000072762. Merifield, E.; Thomas, E. J. J. Chem. Soc., Chem. Commun. 1990,464\u2013466. doi:10.1039/C3990000046463. Merifield, E.; Thomas, E. J. J. Chem. Soc., Perkin Trans. 1 1999,3269\u20133283. doi:10.1039/A906412E64. Trost, B. M.; Ohmori, M.; Boyd, S. A.; Okawara, H.; Brickner, S. J.J. Am. Chem. Soc. 1989, 111, 8281\u20138284. doi:10.1021/ja00203a04265. Vedejs, E.; Rodgers, J. D.; Wittenberger, S. J. J. Am. Chem. Soc.1988, 110, 4822\u20134823. doi:10.1021/ja00222a04766. Vedejs, E.; Wittenberger, S. J. J. Am. Chem. Soc. 1990, 112,4357\u20134364. doi:10.1021/ja00167a03767. Vedejs, E.; Reid, J. G.; Rodgers, J. D.; Wittenberger, S. J.J. Am. Chem. Soc. 1990, 112, 4351\u20134357. doi:10.1021/ja00167a03668. Haidle, A. M.; Myers, A. G. Proc. Natl. Acad. Sci. U. S. A. 2004, 101,12048\u201312053. doi:10.1073/pnas.040211110169. Dombrowski, A. W.; Bills, G. F.; Sabnis, G.; Koupal, L. R.; Meyer, R.;Ondeyka, J. G.; Giacobbe, R. A.; Monaghan, R. L.; Lingham, R. B.J. Antibiot. 1992, 45, 671\u2013678. doi:10.7164/antibiotics.45.67170. Ondeyka, J.; Hensens, O. D.; Zink, D.; Ball, R.; Lingham, R. B.;Bills, G.; Dombrowski, A.; Goetz, M. J. Antibiot. 1992, 45, 679\u2013685.doi:10.7164/antibiotics.45.679 71. Lingham, R. B.; Hsu, A.; Silverman, K. C.; Bills, G. F.;Dombrowski, A.; Goldman, M. E.; Darke, P. L.; Huang, L.; Koch, G.;Ondeyka, J. G.; Goetz, M. A. J. Antibiot. 1992, 45, 686\u2013691.doi:10.7164/antibiotics.45.686 72. Hungate, R. W.; Chen, J. L.; Starbuck, K. E.; Macaluso, S. A.;Rubino, R. S. Tetrahedron Lett. 1996, 37, 4113\u20134116.doi:10.1016/0040-4039(96)00778-2 73. Canham, S. M.; Overman, L. E.; Tanis, P. S. Tetrahedron 2011, 67,9837\u20139843. doi:10.1016/j.tet.2011.09.07974. Zhang, Y.; Wang, T.; Pei, Y.; Hua, H.; Feng, B. J. Antibiot. 2002, 55,693\u2013695. doi:10.7164/antibiotics.55.69375. Moniot, J. L.; Hindenlang, D. M.; Shamma, M. J. Org. Chem. 1979,44, 4347\u20134351. doi:10.1021/jo01338a02276. Fajardo, V.; Elango, V.; Cassels, B. K.; Shamma, M. Tetrahedron Lett.1982, 23, 39\u201342. doi:10.1016/S0040-4039(00)97526-977. Valencia, E.; Freyer, A. J.; Shamma, M.; Fajardo, V. Tetrahedron Lett.1984, 25, 599\u2013602. doi:10.1016/S0040-4039(00)99948-978. Valencia, E.; Weiss, I.; Firdous, S.; Freyer, A. J.; Shamma, M.;Urz\u00fas, A.; Fajardo, V. Tetrahedron 1984, 40, 3957\u20133962.doi:10.1016/0040-4020(84)85073-5 79. Valencia, E.; Fajardo, V.; Freyer, A. J.; Shamma, M. Tetrahedron Lett.1985, 26, 993\u2013996. doi:10.1016/S0040-4039(00)98494-680. Dewick, P. M. Medicinal natural products: a biosynthetic approach,2nd ed.; Wiley: Chichester, 2002.81. Leonard, M. S. ARKIVOC 2013, 1, 1\u201365.82. Evans, P. A.; Holmes, A. B. Tetrahedron 1991, 47, 9131\u20139166.doi:10.1016/S0040-4020(01)96203-9 83. Bentley, K. W. Nat. Prod. Rep. 1997, 14, 387\u2013411.doi:10.1039/np9971400387 84. Fang, F. G.; Feigelson, G. B.; Danishefsky, S. J. Tetrahedron Lett.1989, 30, 2743\u20132746. doi:10.1016/S0040-4039(00)99114-785. Yoneda, R.; Sakamoto, Y.; Oketo, Y.; Harusawa, S.; Kurihara, T.Tetrahedron 1996, 52, 14563\u201314576.doi:10.1016/0040-4020(96)00900-3 86. Sano, T.; Toda, J.; Kashiwaba, N.; Ohshima, T.; Tsuda, Y.Chem. Pharm. Bull. 1987, 35, 479\u2013500. doi:10.1248/cpb.35.47987. Shamma, M.; Moniot, J. L. Isoquinoline alkaloids research,1972-1977; Plenum Press: New York, 1978.doi:10.1007/978-1-4615-8819-1 88. Achari, B.; Chakrabarty, S.; Bandyopadyay, S.; Pakrashi, S.Heterocycles 1982, 19, 1203\u20131206. doi:10.3987/R-1982-07-120389. Mix, D. B.; Guinaudeau, H.; Shamma, M. J. Nat. Prod. 1982, 45,657\u2013666. doi:10.1021/np50024a00190. Chia, Y.-C.; Chang, F.-R.; Teng, C.-M.; Wu, Y.-C. J. Nat. Prod. 2000,63, 1160\u20131163. doi:10.1021/np000063v91. Kim, J. K.; Kim, Y. H.; Nam, H. T.; Kim, B. T.; Heo, J.-N. Org. Lett.2008, 10, 3543\u20133546. doi:10.1021/ol801291k92. Kumar, V.; Poonam; Prasad, A. K.; Parmar, V. S. Nat. Prod. Rep.2003, 20, 565\u2013583. doi:10.1039/b303648k93. Bentley, K. W. Nat. Prod. Rep. 2000, 17, 247\u2013268.doi:10.1039/a900251k 94. Bentley, K. W. Nat. Prod. Rep. 2001, 18, 148\u2013170.doi:10.1039/a909672h 95. Bentley, K. W. Nat. Prod. Rep. 2002, 19, 332\u2013356.doi:10.1039/b009713f 96. Bentley, K. W. The isoquinoline alkaloids; Harwood Academic Pub.:Amsterdam, 1998.97. Spenser, I. D.; Tiwari, H. P. Chem. Commun. 1966, 55\u201356.doi:10.1039/c19660000055 98. Sch\u00fctte, H. R.; Orban, U.; Mothes, K. Eur. J. Biochem. 1967, 1,70\u201372. doi:10.1111/j.1432-1033.1967.tb00045.x99. Comer, F.; Tiwari, H. P.; Spenser, I. D. Can. J. Chem. 1969, 47,481\u2013487. doi:10.1139/v69-070100.Sharma, V.; Jain, S.; Bhakuni, D. S.; Kapil, R. S.J. Chem. Soc., Perkin Trans. 1 1982, 1153\u20131155.doi:10.1039/P19820001153 101.Fugmann, B.; Steglich, W.; Lang-Fugmann, S.; Adam, G. RoemppEncyclopedia Natural Products; Thieme Medical Publishers: Stuttgart,2000. 102.Arlt, V. M.; Stiborova, M.; Schmeiser, H. H. Mutagenesis 2002, 17,265\u2013277. doi:10.1093/mutage/17.4.265103.Mei, N.; Arlt, V. M.; Phillips, D. H.; Heflich, R. H.; Chen, T. Mutat. Res.2006, 602, 83\u201391. doi:10.1016/j.mrfmmm.2006.08.004104.Zhang, Y.-N.; Zhong, X.-G.; Zheng, Z.-P.; Hu, X.-D.; Zuo, J.-P.;Hu, L.-H. Bioorg. Med. Chem. 2007, 15, 988\u2013996.doi:10.1016/j.bmc.2006.10.034 105.Chen, Y.-C.; Chen, J.-J.; Chang, Y.-L.; Teng, C.-M.; Lin, W.-Y.;Wu, C.-C.; Chen, I.-S. Planta Med. 2004, 70, 174\u2013177.doi:10.1055/s-2004-815497 106.Mata, R.; Morales, I.; P\u00e9rez, O.; Rivero-Cruz, I.; Acevedo, L.;Enriquez-Mendoza, I.; Bye, R.; Franzblau, S.; Timmermann, B.J. Nat. Prod. 2004, 67, 1961\u20131968. doi:10.1021/np0401260107.Kim, S. R.; Sung, S. H.; Kang, S. Y.; Koo, K. A.; Kim, S. H.; Ma, C. J.;Lee, H.-S.; Park, M. J.; Kim, Y. C. Planta Med. 2004, 70, 391\u2013396.doi:10.1055/s-2004-818964 108.Marti, G.; Eparvier, V.; Morleo, B.; Le Ven, J.; Apel, C.; Bodo, B.;Amand, S.; Dumontet, V.; Lozach, O.; Meijer, L.; Gu\u00e9ritte, F.;Litaudon, M. Molecules 2013, 18, 3018\u20133027.doi:10.3390/molecules18033018 Beilstein J. Org. Chem. 2013, 9, 2048\u20132078.2077 109.Hegde, V. R.; Borges, S.; Pu, H.; Patel, M.; Gullo, V. P.; Wu, B.;Kirschmeier, P.; Williams, M. J.; Madison, V.; Fischmann, T.;Chan, T.-M. Bioorg. Med. Chem. Lett. 2010, 20, 1384\u20131387.doi:10.1016/j.bmcl.2010.01.007 110.Est\u00e9vez, J. C.; Est\u00e9vez, R. J.; Castedo, L. Tetrahedron 1995, 51,10801\u201310810. doi:10.1016/0040-4020(95)00644-N111.Couture, A.; Deniau, E.; Grandclaudon, P.; Hoarau, C. J. Org. Chem.1998, 63, 3128\u20133132. doi:10.1021/jo972247t112.Couture, A.; Deniau, E.; Grandclaudon, P.; Rybalko-Rosen, H.;L\u00e9once, S.; Pfeiffer, B.; Renard, P. Bioorg. Med. Chem. Lett. 2002,12, 3557\u20133559. doi:10.1016/S0960-894X(02)00794-1113.Benesch, L.; Bury, P.; Guillaneux, D.; Houldsworth, S.; Wang, X.;Snieckus, V. Tetrahedron Lett. 1998, 39, 961\u2013964.doi:10.1016/S0040-4039(97)10670-0 114.Boente, J. M.; Castedo, L.; Dom\u00ednguez, D.; Fari\u00f1a, A.; De Lera, A. R.;Villaverde, M. C. Tetrahedron Lett. 1984, 25, 889\u2013892.doi:10.1016/S0040-4039(01)80054-X 115.Boente, J. M.; Castedo, L.; De Lera, A. R.; Sa\u00e1, J. M.; Suau, R.;Vidal, M. C. Tetrahedron Lett. 1984, 25, 1829\u20131830.doi:10.1016/S0040-4039(01)90052-8 116.Tojo, E.; Dominguez, D.; Castedo, L. Phytochemistry 1991, 30,1005\u20131010. doi:10.1016/0031-9422(91)85296-C117.Manske, R. H. F. Can. J. Res., Sect. B 1938, 16, 81\u201390.118.Manske, R. H. F. J. Am. Chem. Soc. 1950, 72, 55\u201359.doi:10.1021/ja01157a017 119.Bhacca, N. S.; Craig, J. C.; Manske, R. H. F.; Roy, S. K.;Shamma, M.; Slusarchyk, W. A. Tetrahedron 1966, 22, 1467\u20131475.doi:10.1016/S0040-4020(01)99444-X 120.Kametani, T.; Shibuya, S. J. Chem. Soc. 1965, 5565\u20135566.doi:10.1039/jr9650005565 121.Campello, M. J.; Castedo, L.; Dominguez, D.; De Lera, A. R.;Sa\u00e1, J. M.; Suau, R.; Tojo, E.; Vidal, M. C. Tetrahedron Lett. 1984, 25,5933\u20135936. doi:10.1016/S0040-4039(01)81724-X122.Suau, R.; Rico, R.; L\u00f3pez-Romero, J. M.; N\u00e1jera, F.; Ruiz, A.;L\u00f3pez, F. J. O. ARKIVOC 2002, No. 5, 62\u201372.doi:10.3998/ark.5550190.0003.508 123.Blaschke, G.; Scriba, G. Phytochemistry 1985, 25, 111\u2013113.doi:10.1016/S0031-9422(00)94512-6 124.Mueller, M. J.; Zenk, M. H. Liebigs Ann. Chem. 1993, 557\u2013563.doi:10.1002/jlac.199319930191 125.De Lera, A. R.; Suau, R.; Castedo, L. J. Heterocycl. Chem. 1987, 24,313\u2013319. doi:10.1002/jhet.5570240204126.Lamas, C.; Castedo, L.; Dominguez, D. Tetrahedron Lett. 1990, 31,6247\u20136248. doi:10.1016/S0040-4039(00)97036-9127.Suau, R.; L\u00f3pezRomero, J. M.; Rico, R. Tetrahedron Lett. 1996, 37,9357\u20139360. doi:10.1016/S0040-4039(97)82963-2128.Moreau, A.; Couture, A.; Deniau, E.; Grandclaudon, P. J. Org. Chem.2004, 69, 4527\u20134530. doi:10.1021/jo049869g129.Cornforth, J. W. Chem. Br. 1968, 4, 102\u2013106.130.Kamigauchi, T.; Fujiwara, T.; Tani, H.; Kawamura, Y.; Horibe, I.Sesquiterpene derivatives having antiviral activity. W.O. Patent9711947 A1, April 3, 1997.131.Jarvis, B. B.; Salemme, J.; Morals, A. Nat. Toxins 1995, 3, 10\u201316.doi:10.1002/nt.2620030104 132.Roggo, B. E.; Petersen, F.; Sills, M.; Roesel, J. L.; Moerker, T.;Peter, H. H. J. Antibiot. 1996, 49, 13\u201319. doi:10.7164/antibiotics.49.13133.Xu, X.; De Guzman, F. S.; Gloer, J. B.; Shearer, C. A. J. Org. Chem.1992, 57, 6700\u20136703. doi:10.1021/jo00051a006134.Nozawa, Y.; Ito, M.; Sugawara, K.; Hanada, K.; Mizoue, K. J. Antibiot.1997, 50, 641\u2013645. doi:10.7164/antibiotics.50.641135.Shinohara, C.; Hasumi, K.; Hatsumi, W.; Endo, A. J. Antibiot. 1996,49, 961\u2013966. doi:10.7164/antibiotics.49.961136.Hinkley, S. F.; Fettinger, J. C.; Dudley, K.; Jarvis, B. B. J. Antibiot.1999, 52, 988\u2013997. doi:10.7164/antibiotics.52.988137.Kawagishi, H.; Ando, M.; Mizuno, T. Tetrahedron Lett. 1990, 31,373\u2013376. doi:10.1016/S0040-4039(00)94558-1138.Yaoita, Y.; Danbara, K.; Kikuchi, M. Chem. Pharm. Bull. 2005, 53,1202\u20131203. doi:10.1248/cpb.53.1202139.Scherlach, K.; Schuemann, J.; Dahse, H.-M.; Hertweck, C. J. Antibiot.2010, 63, 375\u2013377. doi:10.1038/ja.2010.46140.Geris, R.; Simpson, T. J. Nat. Prod. Rep. 2009, 26, 1063\u20131094.doi:10.1039/b820413f 141.Minagawa, K.; Kouzuki, S.; Yoshimoto, J.; Kawamura, Y.; Tani, H.;Iwata, T.; Terui, Y.; Nakai, H.; Yagi, S.; Hattori, N.; Fujiwara, T.;Kamigauchi, T. J. Antibiot. 2002, 55, 155\u2013164.doi:10.7164/antibiotics.55.155 142.Schroeckh, V.; Scherlach, K.; N\u00fctzmann, H. W.; Shelest, E.;Schmidt-Heck, W.; Schuemann, J.; Martin, K.; Hertweck, C.;Brakhage, A. A. Proc. Natl. Acad. Sci. U. S. A. 2009, 106,14558\u201314563. doi:10.1073/pnas.0901870106143.Kuan, K. K. W.; Pepper, H. P.; Bloch, W. M.; George, J. H. Org. Lett.2012, 14, 4710\u20134713. doi:10.1021/ol301715u144.Sakurai, J.; Kikuchi, T.; Takahashi, O.; Watanabe, K.; Katoh, T.Eur. J. Org. Chem. 2011, 2948\u20132957. doi:10.1002/ejoc.201100173145.Nakamura, M.; Ito, Y.; Ogawa, K.; Michisuji, Y.; Sato, S.; Takada, M.;Hayashi, M.; Yaginuma, S.; Yamamoto, S. J. Antibiot. 1995, 48,1389\u20131395. doi:10.7164/antibiotics.48.1389146.Kende, A. S.; Deng, W.-P.; Zhong, M.; Guo, X.-C. Org. Lett. 2003, 5,1785\u20131788. doi:10.1021/ol030039j147.Li, E.; Jiang, L.; Guo, L.; Zhang, H.; Che, Y. Bioorg. Med. Chem.2008, 16, 7894\u20137899. doi:10.1016/j.bmc.2008.07.075148.Cueto, M.; Jensen, P. R.; Kauffman, C.; Fenical, W.; Lobkovsky, E.;Clardy, J. J. Nat. Prod. 2001, 64, 1444\u20131446. doi:10.1021/np0102713149.Slavov, N.; Cvengro\u0161, J.; Neud\u00f6rfl, J. M.; Schmalz, H.-G.Angew. Chem., Int. Ed. 2010, 49, 7588\u20137591.doi:10.1002/anie.201003755 150.Dalisay, D. S.; Morinaka, B. I.; Skepper, C. K.; Molinski, T. F.J. Am. Chem. Soc. 2009, 131, 7552\u20137553. doi:10.1021/ja9024929151.Flores, B.; Molinski, T. F. Org. Lett. 2011, 13, 3932\u20133935.doi:10.1021/ol201461n 152.West, L. M.; Northcote, P. T.; Battershill, C. N. J. Org. Chem. 2000,65, 445\u2013449. doi:10.1021/jo991296y153.Bai, R. L.; Paull, K. D.; Herald, C. L.; Malspeis, L.; Pettit, G. R.;Hamel, E. J. Biol. Chem. 1991, 266, 15882\u201315889.154.Xiao, Q.; Young, K.; Zakarian, A. Org. Lett. 2013, 15, 3314\u20133317.doi:10.1021/ol401354a 155.Alvarez-Mico, X.; Jensen, P. R.; Fenical, W.; Hughes, C. C. Org. Lett.2013, 15, 988\u2013991. doi:10.1021/ol303374e156.Hughes, C. C.; Prieto-Davo, A.; Jensen, P. R.; Fenical, W. Org. Lett.2008, 10, 629\u2013631. doi:10.1021/ol702952n157.Matsumoto, N.; Tsuchida, T.; Maruyama, M.; Sawa, R.; Kinoshita, N.;Homma, Y.; Takahashi, Y.; Iinuma, H.; Naganawa, H.; Sawa, T.;Hamada, M.; Takeuchi, T. J. Antibiot. 1996, 49, 953\u2013954.doi:10.7164/antibiotics.49.953 158.H\u00f6ltzel, A.; Dieter, A.; Schmid, D. G.; Brown, R.; Goodfellow, M.;Beil, W.; Jung, G.; Fiedler, H.-P. J. Antibiot. 2003, 56, 1058\u20131061.doi:10.7164/antibiotics.56.1058 159.Zhang, X.; Alemany, L. B.; Fiedler, H.-P.; Goodfellow, M.; Parry, R. J.Antimicrob. Agents Chemother. 2008, 52, 574\u2013585.doi:10.1128/AAC.00717-07 Beilstein J. Org. Chem. 2013, 9, 2048\u20132078.2078 160.Moore, B. S.; Hertweck, C. Nat. Prod. Rep. 2002, 19, 70\u201399.doi:10.1039/b003939j 161.Adachi, S.; Watanabe, K.; Iwata, Y.; Kameda, S.; Miyaoka, Y.;Onozuka, M.; Mitsui, R.; Saikawa, Y.; Nakata, M.Angew. Chem., Int. Ed. 2013, 52, 2087\u20132091.doi:10.1002/anie.201209205 162.Cox, C. D.; Siu, T.; Danishefsky, S. J. Angew. Chem., Int. Ed. 2003,42, 5625\u20135629. doi:10.1002/anie.200352591163.Siu, T.; Cox, C. D.; Danishefsky, S. J. Angew. Chem., Int. Ed. 2003,42, 5629\u20135634. doi:10.1002/anie.200352592164.Tatsuta, K.; Tanaka, H.; Tsukagoshi, H.; Kashima, T.; Hosokawa, S.Tetrahedron Lett. 2010, 51, 5546\u20135549.doi:10.1016/j.tetlet.2010.08.035 165.Watanabe, K.; Iwata, Y.; Adachi, S.; Nishikawa, T.; Yoshida, Y.;Kameda, S.; Ide, M.; Saikawa, Y.; Nakata, M. J. Org. Chem. 2010, 75,5573\u20135579. doi:10.1021/jo100913s166.Kato, K.; Sasaki, T.; Takayama, H.; Akita, H. Tetrahedron 2003, 59,2679\u20132685. doi:10.1016/S0040-4020(03)00300-4167.Wang, F.-P.; Liang, X.-T. C20-diterpenoid alkaloids. The Alkaloids.Chemistry and Biology; Academic Press, 2002; Vol. 59, pp 1\u2013280.doi:10.1016/S0099-9598(02)59008-8 168.Wang, F.-P.; Chen, Q.-H.; Liu, X.-Y. Nat. Prod. Rep. 2010, 27,529\u2013570. doi:10.1039/b916679c169.Ochiai, E.; Okamoto, T.; Sakai, S.-i.; Saito, A. Yakugaku Zasshi 1956,76, 1414\u20131418.170.Sakai, S.; Yamamoto, I.; Yamaguchi, K.; Takayama, H.; Ito, M.;Okamoto, T. Chem. Pharm. Bull. 1982, 30, 4579\u20134582.doi:10.1248/cpb.30.4579 171.Jacobs, W. A.; Craig, L. C. J. Biol. Chem. 1942, 143, 605\u2013609.172.Przybylska, M. Can. J. Chem. 1962, 40, 566\u2013568.doi:10.1139/v62-087 173.Suginome, H.; Kakimoto, S.; Sonoda, J.; Noguchi, S. Proc. Jpn. Acad.1946, 22, 122.174.Pelletier, S. W.; Wright, L. H.; Newton, M. G.; Wright, H.J. Chem. Soc. D 1970, 98\u201399. doi:10.1039/c29700000098175.Suginome, H.; Shimanouti, F. Justus Liebigs Ann. Chem. 1940, 545,220\u2013228. doi:10.1002/jlac.19405450121176.Okamoto, T. Chem. Pharm. Bull. 1959, 7, 44\u201349.doi:10.1248/cpb.7.44 177.Muratake, H.; Natsume, M. Angew. Chem., Int. Ed. 2004, 43,4646\u20134649. doi:10.1002/anie.200460332178.Peese, K. M.; Gin, D. Y. J. Am. Chem. Soc. 2006, 128, 8734\u20138735.doi:10.1021/ja0625430 179.Peese, K. M.; Gin, D. Y. Chem.\u2013Eur. J. 2008, 14, 1654\u20131665.doi:10.1002/chem.200701290 License and TermsThis is an Open Access article under the terms of theCreative Commons Attribution License(http://creativecommons.org/licenses/by/2.0), whichpermits unrestricted use, distribution, and reproduction inany medium, provided the original work is properly cited.The license is subject to the Beilstein Journal of OrganicChemistry terms and conditions:(http://www.beilstein-journals.org/bjoc) The definitive version of this article is the electronic onewhich can be found at:doi:10.3762/bjoc.9.243",
    "content": [
        "2048",
        "The chemistry of isoindole natural",
        "productsKlaus Speck and Thomas",
        "Magauer*Review Open AccessAddress: Department of Chemistry, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen,Butenandtstra\u00dfe 5\u201313, 81377 M\u00fcnchen, GermanyEmail: Thomas Magauer* -thomas.magauer@lmu.de* Corresponding authorKeywords: isoindole; isoindoline; isoindolinone; isoindolone; natural productsBeilstein J. Org. Chem. 2013, 9, 2048\u20132078.doi:10.3762/bjoc.9.243 Received: 12 July 2013Accepted: 18 September 2013Published: 10 October 2013This article is part of the Thematic Series \"Natural products in synthesisand biosynthesis\" and is dedicated to Prof. Dr. Wolfgang Steglich on theoccasion of his 80th birthday.Guest Editor: J. S. Dickschat\u00a9 2013 Speck and Magauer; licensee Beilstein-Institut.License and terms: see end of",
        "document.Abstract This review highlights the chemical and biological aspects of natural products containing an oxidized or reduced isoindole skeleton.This motif is found in its intact or modified form in indolocarbazoles, macrocyclic polyketides (cytochalasan alkaloids), theaporhoeadane alkaloids, meroterpenoids from Stachybotrys species and anthraquinone-type alkaloids. Concerning their biologicalactivity, molecular structure and synthesis, we have limited this review to the most inspiring examples. Within different congeners,we have selected a few members and discussed the synthetic routes in more detail. The putative biosynthetic pathways of thepresented isoindole alkaloids are described as",
        "well.Introduction Isoindole (2H-isoindole, 1), known since more than a century,consists of a fused benzopyrrole ring system and constitutes theregioisomer of the abundant 1H-indole heterocycle. The fullyreduced member of the isoindole family is termed isoindoline(2,3-dihydro-1H-isoindole, 2). Formal oxidation to the 10\u03c0-system leads to isoindole (1), which is usually only stable whenthe labile ortho-quinoid structure is embedded in a \u03c0-system [1].Incorporation of additional oxygen gives the isoindolinone (1,3-dihydro-2H-isoindole-1-one, 3) and phthalimide (1,3-dihydro-2H-isoindole-1,3-dione, 4) substitution",
        "pattern.The isoindole structure has attracted scientists for decades andcan be found in several natural and pharmaceutical compounds[2,3]. A number of structures were explored over the years andpromising drug conjugates such as 5\u201311 could be developed(Figure",
        "1).Compared to the synthesis of indoles, where a number ofnamed-reactions have been reported, only conventionalmethods are used for the related isoindole motif. For theconstruction of this rare skeleton inter-and intramolecularDiels\u2013Alder reactions are one of the most powerful methods.This was also exemplified by medicinal chemists fromAstraZeneca in the manufacturing route to an mGluR2 positiveallosteric modulator [4]. In 2012, a programmable enantiose-lective one-pot synthesis of isoindolines was reported",
        "Beilstein J. Org. Chem. 2013, 9,",
        "2048\u20132078.2049",
        "Figure 1: a) Structural features and b) selected examples of non-natural",
        "Beilstein J. Org. Chem. 2013, 9,",
        "2048\u20132078.2050",
        "Scheme 2: Staining amines with 1,4-diketone 19 (R =",
        "Beilstein J. Org. Chem. 2013, 9,",
        "2048\u20132078.2051",
        "Figure 2: Representative members of the indolocarbazole alkaloid",
        "Beilstein J. Org. Chem. 2013, 9,",
        "2048\u20132078.2052",
        "Scheme 3: Biosynthesis of staurosporine",
        "Beilstein J. Org. Chem. 2013, 9,",
        "2048\u20132078.2053",
        "Scheme 4: Wood\u2019s synthesis of K-252a via the common intermediate",
        "Beilstein J. Org. Chem. 2013, 9,",
        "2048\u20132078.2054",
        "ketone 48 was reduced and regioselectively methylated at theC3\u2019 position. Cleavage of the protecting group gave 49,whereas 50 was obtained after dehydration using Martin\u2019ssulfurane, dihydroxylation and a final deprotection",
        "step.Scheme 5: Synthesis of 26, 27, 49 and 50 diverging from the commonintermediate",
        "48.Macrocyclic polyketides: The first cytochalasan alkaloids,cytochalasin A (51) and B (52), originally named phomins [39],were isolated in 1966 [39-42]. Since then, the number of naturalproducts belonging to this family has increased to over 80.Some representative members are depicted in Figure 5 [43].Cyctochalasan alkaloids display a wide range of biologicalproperties, such as cytotoxic, antimicrobial, antiviral and phyto-toxic activities and were reviewed in detail by Hertweck in2010 [44]. Structurally, they consist of one amino acid and ahighly substituted hydroisoindolone moiety fused to a macro-cyclic ring (ring size 9\u201314). In certain cases, the ring system canbe oxidized to an unusual cyclic carbonate as observed forcytochalasin E (53). Depending on the amino acid incorporatedin the isoindolone moiety, the cytochalasans can be furthersubdivided into cytochalasins [41] (phenylalanine), chaetoglo-bosins [45,46] (tryptophan), aspochalasins [47] (leucine),pyrichalasins [48] (tyrosine) or alachalasins [49,50]",
        "(alanine).The biosynthesis of cytochalasans was established on the basisof various isotope labeling experiments using cytochalasin B(52) as a model system [51-55]. It was hypothesized that thecarbon backbone, which is connected to an amino acid, mostlikely originates from a polyketide synthase (PKS)/nonribo-somal peptide synthetase (NRPS) hybrid machinery [56]. Thediscovery of a gene locus for a PKS-NRPS synthetase of thechaetoglobosin producing fungus Penicillium expansum led to amore sophisticated biosynthetic insight of chaetoglobosin A(57) (Scheme 6). The stepwise assembly of the nonaketide 61 isrealized from activated tryptophan (36), one acetyl-CoA (59)starter and eight malonyl-CoA extender (60) units. Theremaining methyl groups are believed to be installed byS-adenosyl methionine (SAM). An intramolecular Aldol con-densation generates the pyrrolinone 62, which reacts via an[4 + 2]-cycloaddition to prochaetoglobosin I (63) [56].Recently, gene disruption studies of Chaetomium globosumrevealed the enzymes involved in the final oxidative transfor-mations leading to chaetoglobosin A (57)",
        "[57].The diverse biological activities and unique molecular architec-ture of the cytochalasan alkaloids have made them a famoussynthetic target. Total syntheses of several members of thecytochalasans were reported, which were reviewed by Hertweckand Br\u00e4se [44,58]. In line with the focus on the construction ofthe isoindole component, one can identify the Diels\u2013Alder reac-tion as the most popular strategy. A linear, biomimetic syn-thesis using a late stage intramolecular Diels\u2013Alder reactionwas implemented in the Stork synthesis of cytochalasin B (52)[59] and the Thomas synthesis of cytochalasin H, D, G and O[60-63]. An intermolecular reaction was reported for the syn-thesis of aspochalasin B (58) by Trost and Vedejs [64-67]. Thesynthesis of cytochalasin D (70) by Thomas is outlined inScheme 7. The intermediate 67, which contains all of the carbonatoms of the natural product, was synthesized in eight stepsstarting from the advanced building blocks 64, 65 and 66.Selective deprotonation and trapping the so-formed enolate withphenylselenyl chloride gave an intermediate selenide.",
        "Beilstein J. Org. Chem. 2013, 9,",
        "2048\u20132078.2055",
        "Figure 5: Selected members of the cytochalasan alkaloid",
        "Beilstein J. Org. Chem. 2013, 9,",
        "2048\u20132078.2056",
        "Scheme 7: Synthesis of cytochalasin D (70) by Thomas",
        "Beilstein J. Org. Chem. 2013, 9,",
        "2048\u20132078.2057",
        "Scheme 9: Synthesis of aldehyde 85 (R =",
        "Beilstein J. Org. Chem. 2013, 9,",
        "2048\u20132078.2058",
        "Scheme 10: Synthesis of (+)-aspergillin PZ (79) by",
        "Tanis.via intermediate 84 to give the cis-aldehyde 85. However, onlythe diastereomeric trans-aldehyde 83 was isolated in moderateyields from the reaction mixture. The authors concluded that acompeting 2-oxonia-[3,3]-sigmatropic aldol pathway via 82aand 82b might be operative for this system. The stereochemicaloutcome could be attributed to the sterically less demandingtransition state 82b. The epimerization of 83 to 85 proceededvia an intermediate lactone and extended the route by sevensteps.",
        "After having secured the cis-epimer 85, the diene moiety wasintroduced in four steps to give aldehyde 86, which was reactedwith the lithium enolate of lactam 87 to furnish the aldol adduct88 (Scheme 10). Oxidation of the secondary alcohol to thecorresponding ketone and selective selenation with phenylse-lenyl chloride gave 89. Following the reported sequence for thesynthesis of cytochalasin D (70), namely oxidation of theselenide to the selenoxide, elimination and intramolecularDiels\u2013Alder reaction, isoindolinone 90 could be obtained inmoderate yield. Removal of the protecting groups then yieldedaspergillin PZ",
        "(91).Though having established a rather long and low yielding syn-thesis, ample quantities could be obtained for a preliminaryevaluation of the biological activity of 79. In a first screenagainst A2058 melanoma and DU145 prostate cancer cell lines,79 showed to be inactive",
        "[73].Isoindolinones derived from isoquinoline alkaloids: Theaporhoeadane alkaloids, a term designated by Shamma [75], areabundantly found in South American members of the botanicalfamily of Berberis (Berberidaceae). Along with the everpresent isoquinoline berberine (92), the isoindole-containingbenzazepines chilenine (93) [76], lennoxamine (94) [77] andchilenamine (95) [78], the isoquinoline nuevamine (96) [77]and the benzazocine magallanesine (97) [79] were isolated fromdifferent Berberidaceae species (Figure",
        "6).Figure 6: Representative Berberis",
        "alkaloids.Chilenine (93) was the first isoindolobenzazepine alkaloidisolated from Berberis empetrifolia in 1982. The biogenesisproceeds most likely via a Pictet\u2013Spengler reaction of dopamine(99) with 4-hydroxyphenylacetaldehyde (100), both",
        "Beilstein J. Org. Chem. 2013, 9,",
        "2048\u20132078.2059",
        "Scheme 11: Proposed biosynthetic pathway to chilenine",
        "(93).from L-tyrosine (98) (Scheme 11). After oxidation andO-methylation, which is carried out by S-adenosylmethionine(SAM), (S)-reticuline (101) is obtained. Oxidation of theN-methyl group to the iminium ion and cyclization gives thetetracyclic carbon skeleton, which upon further methylation andoxidation furnishes berberine (92) [80]. Prechilenine (102),itself isolated as its O-methyl ether is formed via oxidation [78].A base-catalyzed semipinacol-type rearrangement yields 93[76]. Chilenine (93) can be further transformed to the [4.4.0]-tricycle lennoxamine (94) and the [5.3.0]-ring system chile-namine (95) [77-79]. Other members such as nuevamine (96)and magallanesine (97) contain the corresponding [4.3.0] and[6.3.0]-scaffold.",
        "Since their first isolation in the 80\u2019s of the last century, amyriad of syntheses of these small, sometimes highly function-alized and mainly biological inactive alkaloids have beendescribed in the literature. Most of this work is summarized inan excellent review by Leonard [81]. We confine this section tothe syntheses of magallanesine (97) by Danishefsky and Kuri-hara, which were also mentioned by Evans and Bentley",
        "[82,83].Magallanesine (97), which was isolated in 1985 from Berberisdarwinii, a plant native to southern Chile and Argentina, is thefirst known isoindolobenzazocine alkaloid. The seminal totalsynthesis of 97 was achieved in the group of Danishefsky(Scheme 12) using a dimethylformamide acetal-mediatedcyclodehydration of 105. The isoindole unit of 105 wasprepared from the condensation of 103 and 104.",
        "Oxygen\u2013sulfurScheme 12: Synthesis of magallanesine (97) by Danishefsky",
        "Beilstein J. Org. Chem. 2013, 9,",
        "2048\u20132078.2060",
        "Scheme 13: Kurihara\u2019s synthesis of magallanesine",
        "(85).exchange provided the thiophthalimide 105, which could beconverted to magallanesine (97) via an intramolecular aldolcondensation in one step",
        "[84].In 1996, Kurihara (Scheme 13) reported a [1,2]-Meisenheimerrearrangement followed by an intramolecular Heck cyclizationto elaborate the isoindolobenzazocine moiety [85]. The syn-thesis commenced with the preparation of ester 106 from piper-onal according to a known procedure [86]. A four-step sequenceyielded azetidine 107. After oxidation with hydrogen peroxide,the resulting N-oxide cleanly underwent a [1,2]-Meisenheimerrearrangement upon heating in tetrahydrofuran. The so-formedazocine 108 was converted to amine 109 by hydrogenolysis ofthe N\u2013O bond. Amide formation with acid chloride 110 gave111, which upon sequential oxidation yielded enaminone 112.Finally, the isoindolinone moiety was generated via anintramolecular Heck reaction using tetrakis(triphenylphos-phine)palladium(0) and thallium acetate, to give magallanesine(97) in excellent yield",
        "[85].Aporphine alkaloids: The aristolactam alkaloids are classifiedas members of the aporphine alkaloid family and contain a char-acteristic phenanthrene lactam core. Aristolactams (113\u2013116)along with aristolochic acids (117,118) and 4,5-dioxoapor-phines (119,120) were mainly isolated from Aristolochiaceaebut can also be found in several other plant species (Table 1)[87-92]. Several comprehensive overviews of various aristolac-tams were published by Shamma, Parmar and Bentley [87,92-95].",
        "The co-occurrence of aristolactams, aristolochic acids and 4,5-dioxoaporphines led to the assumption of a close biogeneticrelationship between these three classes [87,96]. The biosyn-thesis of aristolochic acid I (117) was elucidated via labelingexperiments and is depicted in Scheme 14 [97-100]. First, twomolecules of the amino acid L-tyrosine (98) are transformed to(R)-orientaline (121) in a similar fashion as described for thebiogenesis of (S)-reticuline (101) (compare Scheme 11). Ade-aromatizing spirocyclization of 121 leads to (R)-orientali-none (122), which, after reduction of the ketone to the second-ary alcohol 123, undergoes a [1,2]-alkyl migration withconcomitant loss of water. Re-aromatization and dioxolane for-mation gives stephanine (124). It is hypothesized that direct oxi-dation of 124 forms 4,5-dioxoaporphine 125, which uponbenzilic acid rearrangement, N-methyl cleavage and decarboxy-lation provides aristolactam I (113) [96]. Additional oxidationof the amide function furnishes aristolochic acid I",
        "(117).The aristolactams and aristolochic acids have a broad spectrumof biologically interesting properties. Although both can beisolated from the same plants, their biological activity is highlyvariable. Herbal drugs containing aristolochic acids",
        "Beilstein J. Org. Chem. 2013, 9,",
        "2048\u20132078.2061",
        "Table 1: Selected members of the aporphine alkaloid",
        "Beilstein J. Org. Chem. 2013, 9,",
        "2048\u20132078.2062",
        "Scheme 16: Snieckus\u2019 synthesis of piperolactam C",
        "(131).Scheme 15: DNA lesion caused by aristolochic acid I (117)",
        "[102].Interestingly, aristolactams are not mutagenic themselves butshow immunosuppressant [104], antiplatelet [105], antimy-cobacterial [106], neuroprotective [107] activities and are excel-lent inhibitors of cyclin-dependent kinases (CDKs) with IC50values in the nanomolar range [108,109]. CDKs are regulatoryproteins, which play an important role in the cell cycle and areconsidered to be a potential target for anticancer treatment. Thismakes the aristolactams promising lead components for furtherdrug discovery [108]. The similarity of the aromatic moiety ofaristolactams and staurosporines, which are also known to bepotent kinase inhibitors could explain the observed inhibition ofcyclin-dependent kinases [109]. Over the past years, consider-able synthetic efforts have been dedicated to the aristolactamsand the development of non-natural",
        "analogues.Pioneering work was carried out in the groups of Castedo [110]and Couture [111,112]. A beautiful application of a directedortho-metalation (DoM) strategy was reported in the",
        "synthesisScheme 17: Synthesis of aristolactam BII",
        "(104).of piperolactam C (131) by Snieckus (Scheme 16) [113]. Treat-ment of 129 with base afforded aminophenanthrene 130 via aremote lateral metalation\u2013cyclization sequence. Metalation of130 with excess n-butyllithium followed by carbonation thenyielded piperolactam C",
        "(131).In 2008, Heo and coworkers reported the synthesis of severalaristolactams employing a one-pot cross-coupling/aldol conden-sation cascade reaction (Scheme 17) [91]. The synthesiscommenced with the preparation of the isoindolinone buildingblock 134. Friedel\u2013Crafts acetylation of 132, followed by aLieben haloform degradation gave the corresponding acid,which after methylation yielded 133. Bromination and lactamformation afforded isoindolinone 134. The following one-potSuzuki\u2013Miyaura/aldol condensation of 134 with boronic acid135 was carried out at 150 \u00b0C in a microwave reactor and",
        "Beilstein J. Org. Chem. 2013, 9,",
        "2048\u20132078.2063",
        "Figure 7: Representative cularine",
        "Beilstein J. Org. Chem. 2013, 9,",
        "2048\u20132078.2064",
        "Scheme 19: The syntheses of 136 and 137 reported by Castedo and",
        "Suau.regioisomeric iso-cularine sarcocapnidine (141) could serve asbranching points for the synthesis of further cularine deriva-tives. Sequential oxidations of 141, similar to the biosynthesisof the aristolactams (Scheme 14), yields yagonine (146), whichcould be converted to aristoyagonine (136) via a benzilic acid-type rearrangement",
        "[121].The first syntheses of aristoyagonine (136) were reported byCastedo and Suau (Scheme 19) [121,122,125-127]. The ap-proach carried out by Castedo relied on 3-hydroxysarcocapnine(147), which could either be isolated from natural sources orprepared via an Ullmann coupling of a 1-(2-bromobenzyl)-8-hydroxyisoquinoline derivative [121,125]. Oxidation of 147with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) gavethe dioxocularine yagonine (146). The bioinspired, base-medi-ated transformation of 146 to 136 obviously proceeds via abenzilic acid rearrangement\u2013oxidation",
        "sequence.In 1996, the group of Suau accessed aristocularine 137 alongwith 149 in one step from acetamide 148. In the presence ofoxalyl chloride and the Lewis acid tin(IV) chloride, a tandemcyclization (Bischler\u2013Napieralski/Friedel\u2013Crafts acylation reac-tion) was triggered to directly give 137 and 149",
        "[122,127].In 2006, another approach to aristoyagonine (136) was reportedby the group of Couture (Scheme 20) [128]. For the preparationof 136, their previously developed procedures for the",
        "synthesesScheme 20: Synthesis of 136 by",
        "Beilstein J. Org. Chem. 2013, 9,",
        "2048\u20132078.2065",
        "Figure 8: Representative isoindolinone",
        "Beilstein J. Org. Chem. 2013, 9,",
        "2048\u20132078.2066",
        "Scheme 21: Postulated biosynthetic pathway for the formation of 156 (adopted from George)",
        "[143].togenic properties (161) [134]. So far, only a few total syntheseswere accomplished and the exact biosynthetic pathways areunknown.",
        "The sesquiterpenoid stachyflin (156) was first isolated from thefungus Stachybotrys sp. RF-7260 by Shionogi & Co., Ltd.,Japan, in 1997 [130] and shows outstanding antiviral activityagainst the influenza A subtype H1N1 (IC50 = 3 nM), outper-forming current drugs such as amantadine and zanamivir [141].The putative biosynthesis of 156, which contains a pentacyclicring system with a cis-fused decalin is depicted in Scheme 21.Farnesyl pyrophosphate (167), which originates from theterpenoid pathway through the condensation of dimethylallylpyrophosphate (DMAPP, 165) with two units of isopentylpyrophosphate (IPP, 166), and orsellinic acid (168), which isderived from a fungal iterative type I polyketide pathway [142],are connected to give 169. This substrate is already poised for apolyene cyclization cascade, which only has to be triggered viaactivation of the epoxide. After the decalin moiety has formed,two sigmatropic, stereospecific [1,2]-shifts of intermediate 170provide the tertiary carbocation 171, which could be trapped bythe phenolic alcohol to give stachyflin (156)",
        "[143].In 2011, the first enantioselective total synthesis of (+)-stachyflin (156) via a Lewis acid induced domino epoxide-opening/rearrangement/cyclization cascade was accomplishedby the group of Katoh (Scheme 22) [144]. The synthesiscommenced with the conversion of dimethyl 2,6-dihydroxy-terephthalate (172) to nitrile 173 within five consecutive steps.Hydrogenation and lactam formation of 173 gave isoindolinone174, which was converted to bromide 175. Reductive alkyl-ation of the protected Wieland\u2013Miescher ketone 176 with bro-mide 175 using Birch conditions gave 177 as a single diastereo-isomer. Epoxide 178 could be prepared in seven steps from 177,but was obtained as a mixture of inseparable diastereoisomers.The Lewis acid induced key step, a domino epoxide-opening/rearrangement/cyclization cascade, most likely proceeded in astepwise manner via intermediate 179. Activation of theepoxide with boron trifluoride etherate induces the plannedsigmatropic [1,2]-methyl and [1,2]-hydride shifts to generatethe tertiary carbocation at the ring junction. This is then trappedby the phenol to give the pentacyclic compounds 180a and180b. The former diastereoisomer could be converted to 180bvia inversion of the secondary alcohol. Cleavage of the methylether and the 3,4-dimethoxybenzyl (3,4DMB) group of 180b ledto (+)-stachyflin (156). The synthesis proceeded in 25 stepswith an overall yield of",
        "2.6%.Another novel class of isoindolinone-containing natural prod-ucts, categorized as spirodihydrobenzofuranlactams or stachy-botrylactams (157, 181, 182), was isolated from differentStachybotrys species by Jarvis and Roggo between 1995 and1996 (Figure 9) [131,132]. These compounds are antagonists ofendothelin and display strong immunosuppressant",
        "Beilstein J. Org. Chem. 2013, 9,",
        "2048\u20132078.2067",
        "Scheme 22: Synthesis of stachyflin (156) by Katoh",
        "[144].Figure 9: Selected examples of",
        "Beilstein J. Org. Chem. 2013, 9,",
        "2048\u20132078.2068",
        "Scheme 23: Synthesis of stachybotrylactam I",
        "(157).The pseudosymmetric dimer stachybocin A (182), which wasisolated by Ogawa in 1995 [145], constitutes the most potentrepresentative [132]. Oxidation of the isoindolinone unit of 157gives the relatively scarce phthalimide motif, which is presentin stachybotrylactam V",
        "(181).To date, only one enantioselective total synthesis of spirodihy-drobenzofuranlactam I 157 has been published (Scheme 23)[146]. The synthesis carried out by the group of Guocommenced with trans-decalone 183, which was derived fromthe Wieland\u2013Miescher ketone. For the conversion of 183 to the\u03b1,\u03b2-unsaturated aldehyde 184 six steps were necessary.Halogen\u2013metal exchange of 185 with n-butyllithium followedby the addition of 184 gave the carbinol 186 in good yield.Removal of the benzyl groups, cleavage of the tert-butyl groupwith concomitant formation of the methoxy ester (COOt-Bu \u2192COOMe), and global deprotection gave 187. Acid-catalyzed(Amberlyst 15) spiroannulation afforded a 1.7:1 mixture of thebenzofuran and the benzopyran (90% overall conversion). Forthe installation of the isoindolinone, a seven-step sequencesimilar to the one described for stachyflin (156) was",
        "usedScheme 24: Synthesis of pestalachloride A (193) by",
        "Schmalz.(Scheme 23). The arene appendage was desymmetrized viamonobromination and cross coupling with copper cyanideprovided a nitrile. Hydrogenation and lactam formation underbasic conditions completed the synthesis of stachybotrylactam I(157).",
        "Chlorinated isoindolinone alkaloids: Pestalachloride A (193)was isolated from the plant endophytic fungus Pestalotiopsisadusta as a racemate and displays potent antifungal activitiesagainst Fusarium culmorum (IC50 = 0.89 \u00b5M) [147]. Pestalone(192), a natural product and synthetic precursor of 193 showsstrong antibiotic activity against methicillin-resistant Staphylo-coccus aureus (MRSA, MIC = 84 nM) and vancomycin-resis-tant Enterococcus (VRE, MIC = 178 nM) [148]. The structuralsimilarity between pestalachloride A (193) and pestalone (192),which both contain the same prenylated polyketide core imply adirect biosynthetic relationship [147]. The reaction of 192 withan equivalent of ammonia gives a cyclic iminohemiaminal,which first tautomerizes to the hydroxy isoindole and then tothe isoindolinone 193. This biosynthetic transformation wasalso used in the total synthesis of 193 by Schmalz (Scheme",
        "Beilstein J. Org. Chem. 2013, 9,",
        "2048\u20132078.2069",
        "Scheme 25: Proposed mechanism for the BF3-catalyzed metal-free carbonyl\u2013olefin metathesis",
        "[149].[149]. Reaction of lithiated 188 (three steps from commerciallyavailable 5-methylresorcinol) with the aldehyde 189 (doublebromination of 3,5-dimethoxybenzaldehyde) gave the racemicalcohol",
        "190.Oxidation to the benzophenone, installation of the prenyl sidechain and introduction of the formyl group was accomplishedwithin five steps to give 191a (Scheme 25). The envisioneddeprotection of 191a using Lewis acidic conditions led to anunexpected and unprecedented metal-free carbonyl\u2013olefinmetathesis. Coordination of boron trifluoride etherate to 191apromotes the formation of the tertiary carbenium ion 194, whichisomerizes via the oxetane intermediate 195 to the benzyliccation 196. Expulsion of acetone then yields indene 197 inexcellent yield. Avoiding this side reaction could only beachieved by exchanging the methyl ether protecting group for amore labile methoxymethyl ether at the benzophenone stage.The following prenylation and formylation proceeded smoothlyunder the same conditions to give 191b (Scheme 24). Cleavageof the MOM ethers afforded pestalone (192), which could beconverted into 193 in a single step by treatment of 192 withammonia in aqueous ammonium chloride solution (pH",
        "8).Muironolide A (204) was isolated by Molinski from the marinesponge Phorbas sp. in 2009 [150]. The molecular framework ofthis unique natural product has a hexahydro-1H-isoindolinone-triketide, a trans-2-chlorocyclopropane and a trichlorocarbinolester. A first biological evaluation showed that 204 displaysantifungal activity. However, only 90 \u00b5g could be isolated andfurther biological screening was not possible [151]. Severalsponge-derived macrolides have proven to be effective cyto-toxic agents [152,153] and one could speculate that muirono-lide A (204) shares this potential. A first attempt to access 204in the laboratory was reported by Molinski shortly after theisolation (Scheme 26) [151]. Coupling of the dienophileprecursor 198 with sorbic acid (199) gave a tertiary amide,which was converted to 200 via a reduction\u2013oxidationsequence. The asymmetric intramolecular Diels\u2013Alder reactionwas then catalyzed by Kristensens\u2019 catalyst (201) to give 202. Abase-promoted epimerization of the aldehyde and aHorner\u2013Wadsworth\u2013Emmons reaction furnished 203, the mostadvanced intermediate reported so",
        "far.Just recently, the group of Zakarian reported another approachto the fully elaborated isoindolinone core of 204",
        "[154].Chlorizidine A (208) (Scheme 27), a cytotoxic metabolite froma marine Streptomyces species shows an unprecedented5H-pyrrolo[2,1-a]isoindolinone ring system, which is connectedto a dichlorinated pyrrolizine [155]. Chlorizidine A (208) andits semisynthetic derivatives display significant cytotoxic activi-ties against various human cancer cell lines. The IC50 value of208 against the colon cancer cell line HCT-116 was determinedto be in the micromolar range (3.2\u20134.9 \u03bcM) [155]. A firstbiosynthesis was postulated on the basis of the structural simi-larity between 208 and marinopyrrole A, another secondarymetabolite derived from a marine Streptomyces species [156].The common biosynthetic precursor 206 stems from a",
        "Beilstein J. Org. Chem. 2013, 9,",
        "2048\u20132078.2070",
        "Scheme 26: Preparation of the isoindoline core of muironolide A",
        "(204).nonribosomal peptide synthetase (NRPS)/polyketide synthase(PKS) pathway. The amino acid proline is first oxidized andchlorinated by an FADH2-dependent halogenase to give 205,which after extension by the polyketide synthase gives thepolyketides 206 and 207, respectively. The intermolecular con-densation of these two components yields chlorizidine A (208)[155].",
        "Anthraquinone-type alkaloids: Lactonamycin (215) andlactonamycin Z (217) were isolated from Streptomycesrishiriensis and Streptomyces anglieri in 1996 and 2003[157,158]. Both compounds are potent antibacterial agentsagainst Gram-positive bacteria, including methicillin-resistantStaphylococcus aureus (MRSA) and",
        "vancomycin-resistantScheme 27: Proposed biosynthesis of",
        "208.Enterococcus (VRE) [159]. Beyond that, the modest cytotoxicactivity of 215 and 217 against human cancer cell lines makesthem interesting lead components for drug discovery. The IC50values of 215 for different leukemia cell lines range from0.11\u20130.22 \u00b5M. For 217, an IC50 value of 0.32 \u00b5M againstgastric adenocarcinoma was observed [157,158]. The hexa-cyclic aglycone of 215 and 217, lactonamycinone (214),consists of a densely oxygenated fused hydrofuran\u2013hydrofura-none and a naphta[e]isoindole ring system. The core of lactona-mycin (215) is decorated with the 2-deoxysugar \u03b1-L-rhodino-pyranose (216), whereas \u03b1-L-2,6-dideoxyribopyranose (218) isfound in 217. The structure of the aglycone 214 is related totetracenomycins, a family of tetracyclic aromatic polyketides,which are produced by several Streptomyces species [159].Biosynthetic investigations revealed a striking similarity of thegene cluster responsible for the biogenesis of lactonamycinone(214) to those clusters found in tetracenomycin-producingbacteria. Cloning experiments and incorporation of variouslabeled precursors resulted in a first hypothesis for the biogen-esis of 215 and 217 (Scheme 28) [159]. This led to the assump-tion that the aglycone 214 is assembled from nine acetate unitsand glycine, respectively N-methylglycine derivative, whichcontributes both carbon atoms and the nitrogen to the skeletonof 210 (position 12 and 12a). The latter are uncommon",
        "Beilstein J. Org. Chem. 2013, 9,",
        "2048\u20132078.2071",
        "Scheme 28: Model for the biosynthesis of 215 and",
        "217.units in a type II polyketide assembly line [160]. Upon oxida-tive cleavage of the D-ring of the putative tetracenomycin-likeintermediate 210, the aldehyde 211 is reduced to the corres-ponding alcohol 212. Acetalization and introduction of the 1,2-cis-diol moiety furnishes 213. Sequential formation of thelactone and the isoindolinone generates 214. A final glycosyl-ation step leads to lactonamycin (215) and lactonamycin Z(217).",
        "The remarkable structure and the promising biological activi-ties have attracted many synthetic groups. Several totalsyntheses of 215 and 217 were reported in recent years [161](and references therein). The group of Danishefsky was the firstto report a diastereoselective synthesis of lactonamycinone(214) employing a Diels\u2013Alder reaction [162,163]. In 2010,Tastuta completed the first total synthesis of lactonamycin (215)by using a sequential conjugate addition, a stereoselectiveglycosylation reaction and a Michael\u2013Dieckmann-type cycliza-tion [164]. The recently published total synthesis of lactona-mycin (215) and lactonamycin Z (217) by Saikawa and Nakatais based on a late-stage glycosylation strategy (Scheme 29).This enables the specific variation of the sugar components andgives access to various lactonamycin derivatives",
        "[161].Starting from alcohol 219, the diene precursor 220 could beprepared in seven steps. The following Diels\u2013Alder reactionwith chloroethynylquinone 221, which was synthesizedaccording to a known procedure [165] proceeded in a highlyregioselective manner to give antharaquinone 222. Introductionof the fused hydrofuran\u2013hydrofuranone moiety wasaccomplished via deprotection, palladium-catalyzed cycliza-tion\u2013methoxycarbonylation [166] and an acid-catalyzed lactoneformation to afford 223. For the generation of the isoindolinonevia a Bischler\u2013Napieralski reaction, a chloroacetyl (CA)-protected phenol was essential to avoid competing carbamateformation of the starting material. Upon exposure of 223 tophosphorus pentoxide, the desired isoindolinone 224 wasformed in 75% yield. Deprotection led to lactonamycinone(214), which was the substrate for a ytterbium triflate-catalyzedglycosylation to give 215 and 217,",
        "Beilstein J. Org. Chem. 2013, 9,",
        "2048\u20132078.2072",
        "Scheme 29: Synthesis of lactonamycin (215) and lactonamycin Z",
        "(217).Miscellaneous: At first glance, the hetisine alkaloids do notshow any structural similarities with the compound classesdescribed before. However, though lacking an \u201cintact\u201d isoin-dole core, one can spot the corresponding perhydro motif. Sincetheir first discovery more than 70 years ago, more than 100different hetisine alkaloids have been isolated from differentspecies of the plants Aconitum and Delphinium, and to a lesserextend from Rumex, Consolida and Spiraea [167,168]. Theseplants have been widely used in traditional herbal medicine andfurther pharmacological studies revealed that hetisine alkaloidsare highly bioactive compounds [167,168]. The diverse spec-trum includes vasodilatoring, anti-arrhythmic, immunomodu-lating and analgesic activities. Hetisines can be classified,according to Wang and Liang, as C20-diterpenoid alkaloids,which belong to the family of atisane alkaloids [167]. Thehetisines comprise a heptacyclic core and are structurally themost complex members derived from the atisine skeleton. Themost prominent representatives, nominine (225) [169,170],kobusine (226) [171,172], pseudokobusine (227) [173,174] andhetisine (228) [174-176] are depicted in Figure",
        "10.The putative biosynthetic pathway for the formation of the heti-sine alkaloids is derived from phytochemical data and basicbiochemical transformations (Scheme 30) [167]. Cyclization ofgeranylgeranyl pyrophosphate (229), involving the ent-copalyldiphosphate synthase, could give ent-copalyl diphosphate (230).After loss of the pyrophosphate group and double cyclization, a1,3-hydride shift and Wagner\u2013Meerwein rearrangement leads tothe naturally occurring ent-atisir-16-ene (231). Oxidativeincorporation of nitrogen, which might be derived from\u03b2-aminoethanol, generates the atisine-type skeleton 232. Oxida-tive C\u2013C-bond formation gives the hetidine core (233) andC\u2013N-bond formation the hetisine skeleton",
        "(234).The first total synthesis of a hetisine-type alkaloid was accom-plished by Muratake and Natsume in 2004 [177]. In",
        "Beilstein J. Org. Chem. 2013, 9,",
        "2048\u20132078.2073",
        "Figure 10: Hetisine alkaloids",
        "225\u2013228.Scheme 30: Biosynthetic proposal for the formation of the hetisine core",
        "[167].seminal work, (\u00b1)-nominine (225) was synthesized within 40steps and 0.15% overall yield. Two years later, a more conciseand efficient access to (\u00b1)-nominine (225), featuring a oxidoiso-quinolinium-1,3-dipolar cycloaddition and a dienamine-Diels\u2013Alder reaction, was accomplished by Gin (Scheme 31)[178]. Coupling of 235 and 236, both synthesized within threesteps from simple starting materials, via a Staudinger\u2013aza-Wittig reaction gave amine 237 as a mixture of four diastereo-isomers. Conversion into 4-oxido-isoquinolinium betaine 238could be achieved by an acid-catalyzed methanol extrusion andisomerization. Betaine 238 served as the substrate for thefollowing 1,3-aza-dipolar cycloaddition. Carrying out the reac-tion at 180 \u00b0C in tetrahydrofuran provided a separable mixtureof pyrrolidine isomers 241 and 242 (1:3.6). The undesiredcycloadduct 242 could be equilibrated to 241 due to the revers-ibility of the reaction. Conversion to the \u03b2,\u03b3-cyclohexenone",
        "Beilstein J. Org. Chem. 2013, 9,",
        "2048\u20132078.2074",
        "Scheme 31: Synthesis of nominine (225).was accomplished within 6 consecutive steps. Generation of thedienamine 244 with pyrrolidine in methanol at 60 \u00b0C triggeredan intramolecular Diels\u2013Alder reaction to provide the fullcarbon skeleton 245. The final transformations of the synthesisinvolved a Wittig olefination of the ketone and a diastereoselec-tive allylic oxidation to provide (\u00b1)-nominine (225). In 2008,the same group reported the first total synthesis of (+)-nomi-nine by introducing the desired stereochemical information tothe nitrile 235",
        "[179].Conclusion The outlined syntheses of natural products containing theuncommon isoindole skeleton are still far away from beingideal. Low yielding multistep strategies dominate for morecomplex molecules and often cannot provide the amountsnecessary for further investigations. Several biologically activemembers are still precluded from extensive biological studiesdue to their low abundance in nature. This and the fact, thatmany compounds are underexplored offers plenty opportunitiesfor the development of innovative chemical transformations.The biosynthesis of many isoindole natural products is stilluncertain and has yet to be unraveled. The presented examplescould serve as an inspiration for the development of novel syn-thetic methods, new biosynthetic insights and drug develop-ment. Considerably more discoveries remain to be uncoveredthrough exciting",
        "projects.Acknowledgements Support from the Fonds der Chemischen Industrie (Liebig-Stipendium to T.M.) and Prof. Dirk Trauner is gratefullyacknowledged. We thank Prof. Wolfgang Steglich and Dr.David Woodmansee for helpful discussions. We acknowledgethe many scientists whose important discoveries could not beincluded or referenced in this",
        "article.References 1. Heugebaert, T. S. A.; Roman, B. I.; Stevens, C. V. Chem. Soc.",
        "Rev.2012, 41, 5626\u20135640. doi:10.1039/c2cs35093a2. Subbarayappa, A.; Patoliya, P.",
        "U.Indian J. Chem., Sect. B: Org. Chem. Incl. Med. Chem. 2009, 48,545\u2013552. 3. Belliotti, T. R.; Brink, W. A.; Kesten, S. R.; Rubin, J.",
        "R.;Wustrow, D. J.; Zoski, K. T.; Whetzel, S. Z.; Corbin, A. E.;Pugsley, T. A.; Heffner, T. G.; Wise, L. D. Bioorg. Med. Chem. Lett.1998, 8, 1499\u20131502. doi:10.1016/S0960-894X(98)00252-24. Ball, M.; Boyd, A.; Churchill, G.; Cuthbert, M.; Drew, M.; Fielding,",
        "M.;Ford, G.; Frodsham, L.; Golden, M.; Leslie, K.; Lyons, S.;McKeever-Abbas, B.; Stark, A.; Tomlin, P.; Gottschling, S.; Hajar, A.;Jiang, J.-l.; Lo, J.; Suchozak, B. Org. Process Res. Dev. 2012, 16,741\u2013747. doi:10.1021/op300002f5. Potowski, M.; Sch\u00fcrmann, M.; Preut, H.; Antonchick, A.",
        "P.;Waldmann, H. Nat. Chem. Biol. 2012, 8, 428\u2013430.doi:10.1038/nchembio.901",
        "Beilstein J. Org. Chem. 2013, 9,",
        "2048\u20132078.2075",
        "6. Babichev, F. S.; Kovtunenko, V. A.; Tyltin, A. K. Russ. Chem.",
        "Rev.1981, 50, 1087\u20131103. doi:10.1070/RC1981v050n11ABEH0027387. Kovtunenko, V. A.; Voitenko, Z. V. Russ. Chem. Rev. 1994,",
        "63,997\u20131018. doi:10.1070/RC1994v063n12ABEH0001318. Couture, A.; Grandclaudon,",
        "P.Stud. Cercet. Stiint.: Chim. Ing. Chim., Biotehnol., Ind. Aliment. (Univ. Bacau) 2010, 11, 11\u201344.9. Armoiry, X.; Aulagner, G.; Facon, T. J. Clin. Pharm. Ther. 2008,",
        "33,219\u2013226. doi:10.1111/j.1365-2710.2008.00920.x10. Frincke, J. M.; Faulkner, D. J. J. Am. Chem. Soc. 1982, 104,",
        "265\u2013269.doi:10.1021/ja00365a048 11. Schubert-Zsilavecz, M.; Schramm, H. W. Liebigs Ann. Chem.",
        "1991,973. doi:10.1002/jlac.199119910116812. Yu, C.; Xu, Y.; Jiao, L.; Zhou, J.; Wang, Z.; Hao, E. Chem.\u2013Eur.",
        "J.2012, 18, 6437\u20136442. doi:10.1002/chem.20120039813. Maekawa, E.; Suzuki, Y.; Sugiyama, S. Chem. Ber. 1968,",
        "101,847\u2013854. doi:10.1002/cber.1968101031414. Riemschneider, R.; Hennig, K.; Wons, T. Monatsh. Chem. 1987,",
        "118,831\u2013835. doi:10.1007/BF0080923315. M\u00e9dici, R.; de Mar\u00eda, P. D.; Otten, L. G.; Straathof, A. J.",
        "J.Adv. Synth. Catal. 2011, 353, 2369\u20132376.doi:10.1002/adsc.201100386 16. Omura, S.; Iwai, Y.; Hirano, A.; Nakagawa, A.; Awaya,",
        "J.;Tsuchiya, H.; Takahashi, Y.; Asuma, R. J. Antibiot. 1977, 30,275\u2013282. doi:10.7164/antibiotics.30.27517. Schmidt, A. W.; Reddy, K. R.; Kn\u00f6lker, H.-J. Chem. Rev. 2012,",
        "112,3193\u20133328. doi:10.1021/cr200447s18. Tamaoki, T.; Nomoto, H.; Takahashi, I.; Kato, Y.; Morimoto,",
        "M.;Tomita, F. Biochem. Biophys. Res. Commun. 1986, 135, 397\u2013402.doi:10.1016/0006-291X(86)90008-2 19. Prade, L.; Engh, R. A.; Girod, A.; Kinzel, V.; Huber,",
        "R.;Bossemeyer, D. Structure 1997, 5, 1627\u20131637.doi:10.1016/S0969-2126(97)00310-9 20. Hatzimichael, E.; Georgiou, G.; Benetatos, L.; Briasoulis,",
        "E.Am. J. Blood Res. 2013, 3, 29\u201351.21. Yamashita, Y.; Fujii, N.; Murakata, C.; Ashizawa, T.; Okabe,",
        "M.;Nakano, H. Biochemistry 1992, 31, 12069\u201312075.doi:10.1021/bi00163a015 22. Nakano, H.; Omura, S. J. Antibiot. 2009, 62,",
        "17\u201326.doi:10.1038/ja.2008.4 23. Pearce, C. J.; Doyle, T. W.; Forenza, S.; Lam, K. S.; Schroeder, D.",
        "R.J. Nat. Prod. 1988, 51, 937\u2013940. doi:10.1021/np50059a02024. Fr\u00f6de, R.; Hinze, C.; Josten, I.; Schmidt, B.; Steffan, B.; Steglich,",
        "W.Tetrahedron Lett. 1994, 35, 1689\u20131690.doi:10.1016/0040-4039(94)88320-3 25. Hoshino, T.; Kojima, Y.; Hayashi, T.; Uchiyama, T.; Kaneko,",
        "K.Biosci., Biotechnol., Biochem. 1993, 57, 775\u2013781.doi:10.1271/bbb.57.775 26. S\u00e1nchez, C.; Butovich, I. A.; Bra\u00f1a, A. F.; Rohr, J.; M\u00e9ndez,",
        "C.;Salas, J. A. Chem. Biol. 2002, 9, 519\u2013531.doi:10.1016/S1074-5521(02)00126-6 27. Onaka, H.; Taniguchi, S.; Igarashi, Y.; Furumai, T. J. Antibiot.",
        "2002,55, 1063\u20131071. doi:10.7164/antibiotics.55.106328. Onaka, H.; Taniguchi, S.; Igarashi, Y.; Furumai,",
        "T.Biosci., Biotechnol., Biochem. 2003, 67, 127\u2013138.doi:10.1271/bbb.67.127 29. Howard-Jones, A. R.; Walsh, C. T. J. Am. Chem. Soc. 2006,",
        "128,12289\u201312298. doi:10.1021/ja063898m30. Howard-Jones, A. R.; Walsh, C. T. J. Am. Chem. Soc. 2007,",
        "129,11016\u201311017.",
        "doi:10.1021/ja074380131. Sarstedt, B.; Winterfeldt, E. Heterocycles 1983, 20,",
        "469\u2013476.doi:10.3987/R-1983-03-0469 32. Hughes, I.; Nolan, W. P.; Raphael, R.",
        "A.J. Chem. Soc., Perkin Trans. 1 1990, 2475\u20132480.doi:10.1039/P19900002475 33. Moody, C. J.; Rahimtoola, K. F. J. Chem. Soc., Chem.",
        "Commun.1990, 1667\u20131668. doi:10.1039/C3990000166734. Moody, C. J.; Rahimtoola, K. F.; Porter, B.; Ross, B. C. J. Org.",
        "Chem.1992, 57, 2105\u20132114. doi:10.1021/jo00033a03635. Harris, W.; Hill, C. H.; Keech, E.; Malsher, P. Tetrahedron Lett.",
        "1993,34, 8361\u20138364. doi:10.1016/S0040-4039(00)61431-436. Link, J. T.; Raghavan, S.; Danishefsky, S. J. J. Am. Chem. Soc.",
        "1995,117, 552\u2013553. doi:10.1021/ja00106a07237. Wood, J. L.; Stoltz, B. M.; Goodman, S. N. J. Am. Chem. Soc.",
        "1996,118, 10656\u201310657. doi:10.1021/ja962614338. Wood, J. L.; Stoltz, B. M.; Dietrich, H.-J. J. Am. Chem. Soc.",
        "1995,117, 10413\u201310414. doi:10.1021/ja00146a03939. Rothweiler, W.; Tamm, C. Experientia 1966, 22,",
        "750\u2013752.doi:10.1007/BF01901360 40. Rothweiler, W.; Tamm, C. Helv. Chim. Acta 1970, 53,",
        "696\u2013724.doi:10.1002/hlca.19700530404 41. Aldridge, D. C.; Armstrong, J. J.; Speake, R. N.; Turner, W.",
        "B.Chem. Commun. 1967, 26\u201327. doi:10.1039/c1967000002642. Aldridge, D. C.; Armstrong, J. J.; Speake, R. N.; Turner, W.",
        "B.J. Chem. Soc. C 1967, 1667\u20131676. doi:10.1039/J3967000166743. Zhang, D.; Ge, H.; Xie, D.; Chen, R.; Zou, J.-h.; Tao, X.; Dai,",
        "J.Org. Lett. 2013, 15, 1674\u20131677. doi:10.1021/ol400458n44. Scherlach, K.; Boettger, D.; Remme, N.; Hertweck, C. Nat. Prod.",
        "Rep.2010, 27, 869\u2013886. doi:10.1039/b903913a45. Sekita, S.; Yoshihira, K.; Natori, S.; Kuwano, H. Chem. Pharm.",
        "Bull.1982, 30, 1618\u20131628. doi:10.1248/cpb.30.161846. Sekita, S.; Yoshihira, K.; Natori, S.; Kuwano, H. Chem. Pharm.",
        "Bull.1982, 30, 1629\u20131638. doi:10.1248/cpb.30.162947. Zhou, G. X.; Wijeratne, E. M. K.; Bigelow, D.; Pierson, L.",
        "S.;VanEtten, H. D.; Gunatilaka, A. A. L. J. Nat. Prod. 2004, 67, 328\u2013332.doi:10.1021/np030353m 48. Nukina, M. Agric. Biol. Chem. 1987, 51,",
        "2625\u20132628.doi:10.1271/bbb1961.51.2625 49. Zhang, Y.; Tian, R.; Liu, S.; Chen, X.; Liu, X.; Che,",
        "Y.Bioorg. Med. Chem. 2008, 16, 2627\u20132634.doi:10.1016/j.bmc.2007.11.042 50. Zhang, Y.; Tian, R.; Liu, S.; Chen, X.; Liu, X.; Che,",
        "Y.Bioorg. Med. Chem. 2009, 17, 428. doi:10.1016/j.bmc.2007.11.08451. Vederas, J. C.; Graf, W.; David, L.; Tamm, C. Helv. Chim. Acta",
        "1975,58, 1886\u20131898. doi:10.1002/hlca.1975058070452. Vederas, J. C.; Tamm, C. Helv. Chim. Acta 1976, 59,",
        "558\u2013566.doi:10.1002/hlca.19760590221 53. Robert, J.-L.; Tamm, C. Helv. Chim. Acta 1975, 58,",
        "2501\u20132504.doi:10.1002/hlca.19750580830 54. Probst, A.; Tamm, C. Helv. Chim. Acta 1981, 64,",
        "2056\u20132064.doi:10.1002/hlca.19810640710 55. Hadener, A.; Roth, P.; Tamm, C. Z. Naturforsch., C 1989, 44, 19\u201332.56. Sch\u00fcmann, J.; Hertweck, C. J. Am. Chem. Soc. 2007,",
        "129,9564\u20139565. doi:10.1021/ja072884t57. Ishiuchi, K.; Nakazawa, T.; Yagishita, F.; Mino, T.; Noguchi,",
        "H.;Hotta, K.; Watanabe, K. J. Am. Chem. Soc. 2013, 135, 7371\u20137377.doi:10.1021/ja402828w 58. Br\u00e4se, S.; Encinas, A.; Keck, J.; Nising, C. F. Chem. Rev. 2009,",
        "109,3903\u20133990.",
        "Beilstein J. Org. Chem. 2013, 9,",
        "2048\u20132078.2076",
        "59. Stork, G.; Nakamura, E. J. Am. Chem. Soc. 1983, 105,",
        "5510\u20135512.doi:10.1021/ja00354a072 60. Dyke, H.; Sauter, R.; Steel, P.; Thomas, E.",
        "J.J. Chem. Soc., Chem. Commun. 1986, 1447\u20131449.doi:10.1039/C39860001447 61. Thomas, E. J.; Whitehead, J. W. F. J. Chem. Soc., Chem.",
        "Commun.1986, 727\u2013728. doi:10.1039/C3986000072762. Merifield, E.; Thomas, E. J. J. Chem. Soc., Chem. Commun.",
        "1990,464\u2013466. doi:10.1039/C3990000046463. Merifield, E.; Thomas, E. J. J. Chem. Soc., Perkin Trans. 1",
        "1999,3269\u20133283. doi:10.1039/A906412E64. Trost, B. M.; Ohmori, M.; Boyd, S. A.; Okawara, H.; Brickner, S.",
        "J.J. Am. Chem. Soc. 1989, 111, 8281\u20138284. doi:10.1021/ja00203a04265. Vedejs, E.; Rodgers, J. D.; Wittenberger, S. J. J. Am. Chem.",
        "Soc.1988, 110, 4822\u20134823. doi:10.1021/ja00222a04766. Vedejs, E.; Wittenberger, S. J. J. Am. Chem. Soc. 1990,",
        "112,4357\u20134364. doi:10.1021/ja00167a03767. Vedejs, E.; Reid, J. G.; Rodgers, J. D.; Wittenberger, S.",
        "J.J. Am. Chem. Soc. 1990, 112, 4351\u20134357. doi:10.1021/ja00167a03668. Haidle, A. M.; Myers, A. G. Proc. Natl. Acad. Sci. U. S. A. 2004,",
        "101,12048\u201312053. doi:10.1073/pnas.040211110169. Dombrowski, A. W.; Bills, G. F.; Sabnis, G.; Koupal, L. R.; Meyer,",
        "R.;Ondeyka, J. G.; Giacobbe, R. A.; Monaghan, R. L.; Lingham, R. B.J. Antibiot. 1992, 45, 671\u2013678. doi:10.7164/antibiotics.45.67170. Ondeyka, J.; Hensens, O. D.; Zink, D.; Ball, R.; Lingham, R.",
        "B.;Bills, G.; Dombrowski, A.; Goetz, M. J. Antibiot. 1992, 45, 679\u2013685.doi:10.7164/antibiotics.45.679 71. Lingham, R. B.; Hsu, A.; Silverman, K. C.; Bills, G.",
        "F.;Dombrowski, A.; Goldman, M. E.; Darke, P. L.; Huang, L.; Koch, G.;Ondeyka, J. G.; Goetz, M. A. J. Antibiot. 1992, 45, 686\u2013691.doi:10.7164/antibiotics.45.686 72. Hungate, R. W.; Chen, J. L.; Starbuck, K. E.; Macaluso, S.",
        "A.;Rubino, R. S. Tetrahedron Lett. 1996, 37, 4113\u20134116.doi:10.1016/0040-4039(96)00778-2 73. Canham, S. M.; Overman, L. E.; Tanis, P. S. Tetrahedron 2011,",
        "67,9837\u20139843. doi:10.1016/j.tet.2011.09.07974. Zhang, Y.; Wang, T.; Pei, Y.; Hua, H.; Feng, B. J. Antibiot. 2002,",
        "55,693\u2013695. doi:10.7164/antibiotics.55.69375. Moniot, J. L.; Hindenlang, D. M.; Shamma, M. J. Org. Chem.",
        "1979,44, 4347\u20134351. doi:10.1021/jo01338a02276. Fajardo, V.; Elango, V.; Cassels, B. K.; Shamma, M. Tetrahedron",
        "Lett.1982, 23, 39\u201342. doi:10.1016/S0040-4039(00)97526-977. Valencia, E.; Freyer, A. J.; Shamma, M.; Fajardo, V. Tetrahedron",
        "Lett.1984, 25, 599\u2013602. doi:10.1016/S0040-4039(00)99948-978. Valencia, E.; Weiss, I.; Firdous, S.; Freyer, A. J.; Shamma,",
        "M.;Urz\u00fas, A.; Fajardo, V. Tetrahedron 1984, 40, 3957\u20133962.doi:10.1016/0040-4020(84)85073-5 79. Valencia, E.; Fajardo, V.; Freyer, A. J.; Shamma, M. Tetrahedron",
        "Lett.1985, 26, 993\u2013996. doi:10.1016/S0040-4039(00)98494-680. Dewick, P. M. Medicinal natural products: a biosynthetic",
        "approach,2nd ed.; Wiley: Chichester, 2002.81. Leonard, M. S. ARKIVOC 2013, 1, 1\u201365.82. Evans, P. A.; Holmes, A. B. Tetrahedron 1991, 47,",
        "9131\u20139166.doi:10.1016/S0040-4020(01)96203-9 83. Bentley, K. W. Nat. Prod. Rep. 1997, 14,",
        "387\u2013411.doi:10.1039/np9971400387 84. Fang, F. G.; Feigelson, G. B.; Danishefsky, S. J. Tetrahedron",
        "Lett.1989, 30, 2743\u20132746.",
        "doi:10.1016/S0040-4039(00)99114-785. Yoneda, R.; Sakamoto, Y.; Oketo, Y.; Harusawa, S.; Kurihara,",
        "T.Tetrahedron 1996, 52, 14563\u201314576.doi:10.1016/0040-4020(96)00900-3 86. Sano, T.; Toda, J.; Kashiwaba, N.; Ohshima, T.; Tsuda,",
        "Y.Chem. Pharm. Bull. 1987, 35, 479\u2013500. doi:10.1248/cpb.35.47987. Shamma, M.; Moniot, J. L. Isoquinoline alkaloids",
        "research,1972-1977; Plenum Press: New York, 1978.doi:10.1007/978-1-4615-8819-1 88. Achari, B.; Chakrabarty, S.; Bandyopadyay, S.; Pakrashi,",
        "S.Heterocycles 1982, 19, 1203\u20131206. doi:10.3987/R-1982-07-120389. Mix, D. B.; Guinaudeau, H.; Shamma, M. J. Nat. Prod. 1982,",
        "45,657\u2013666. doi:10.1021/np50024a00190. Chia, Y.-C.; Chang, F.-R.; Teng, C.-M.; Wu, Y.-C. J. Nat. Prod.",
        "2000,63, 1160\u20131163. doi:10.1021/np000063v91. Kim, J. K.; Kim, Y. H.; Nam, H. T.; Kim, B. T.; Heo, J.-N. Org.",
        "Lett.2008, 10, 3543\u20133546. doi:10.1021/ol801291k92. Kumar, V.; Poonam; Prasad, A. K.; Parmar, V. S. Nat. Prod.",
        "Rep.2003, 20, 565\u2013583. doi:10.1039/b303648k93. Bentley, K. W. Nat. Prod. Rep. 2000, 17,",
        "247\u2013268.doi:10.1039/a900251k 94. Bentley, K. W. Nat. Prod. Rep. 2001, 18,",
        "148\u2013170.doi:10.1039/a909672h 95. Bentley, K. W. Nat. Prod. Rep. 2002, 19,",
        "332\u2013356.doi:10.1039/b009713f 96. Bentley, K. W. The isoquinoline alkaloids; Harwood Academic",
        "Pub.:Amsterdam, 1998.97. Spenser, I. D.; Tiwari, H. P. Chem. Commun. 1966,",
        "55\u201356.doi:10.1039/c19660000055 98. Sch\u00fctte, H. R.; Orban, U.; Mothes, K. Eur. J. Biochem. 1967,",
        "1,70\u201372. doi:10.1111/j.1432-1033.1967.tb00045.x99. Comer, F.; Tiwari, H. P.; Spenser, I. D. Can. J. Chem. 1969,",
        "47,481\u2013487. doi:10.1139/v69-070100.Sharma, V.; Jain, S.; Bhakuni, D. S.; Kapil, R.",
        "S.J. Chem. Soc., Perkin Trans. 1 1982, 1153\u20131155.doi:10.1039/P19820001153 101.Fugmann, B.; Steglich, W.; Lang-Fugmann, S.; Adam, G.",
        "RoemppEncyclopedia Natural Products; Thieme Medical Publishers: Stuttgart,2000. 102.Arlt, V. M.; Stiborova, M.; Schmeiser, H. H. Mutagenesis 2002,",
        "17,265\u2013277. doi:10.1093/mutage/17.4.265103.Mei, N.; Arlt, V. M.; Phillips, D. H.; Heflich, R. H.; Chen, T. Mutat.",
        "Res.2006, 602, 83\u201391. doi:10.1016/j.mrfmmm.2006.08.004104.Zhang, Y.-N.; Zhong, X.-G.; Zheng, Z.-P.; Hu, X.-D.; Zuo,",
        "J.-P.;Hu, L.-H. Bioorg. Med. Chem. 2007, 15, 988\u2013996.doi:10.1016/j.bmc.2006.10.034 105.Chen, Y.-C.; Chen, J.-J.; Chang, Y.-L.; Teng, C.-M.; Lin,",
        "W.-Y.;Wu, C.-C.; Chen, I.-S. Planta Med. 2004, 70, 174\u2013177.doi:10.1055/s-2004-815497 106.Mata, R.; Morales, I.; P\u00e9rez, O.; Rivero-Cruz, I.; Acevedo,",
        "L.;Enriquez-Mendoza, I.; Bye, R.; Franzblau, S.; Timmermann, B.J. Nat. Prod. 2004, 67, 1961\u20131968. doi:10.1021/np0401260107.Kim, S. R.; Sung, S. H.; Kang, S. Y.; Koo, K. A.; Kim, S. H.; Ma, C.",
        "J.;Lee, H.-S.; Park, M. J.; Kim, Y. C. Planta Med. 2004, 70, 391\u2013396.doi:10.1055/s-2004-818964 108.Marti, G.; Eparvier, V.; Morleo, B.; Le Ven, J.; Apel, C.; Bodo,",
        "B.;Amand, S.; Dumontet, V.; Lozach, O.; Meijer, L.; Gu\u00e9ritte, F.;Litaudon, M. Molecules 2013, 18, 3018\u20133027.doi:10.3390/molecules18033018",
        "Beilstein J. Org. Chem. 2013, 9,",
        "2048\u20132078.2077",
        "109.Hegde, V. R.; Borges, S.; Pu, H.; Patel, M.; Gullo, V. P.; Wu,",
        "B.;Kirschmeier, P.; Williams, M. J.; Madison, V.; Fischmann, T.;Chan, T.-M. Bioorg. Med. Chem. Lett. 2010, 20, 1384\u20131387.doi:10.1016/j.bmcl.2010.01.007 110.Est\u00e9vez, J. C.; Est\u00e9vez, R. J.; Castedo, L. Tetrahedron 1995,",
        "51,10801\u201310810. doi:10.1016/0040-4020(95)00644-N111.Couture, A.; Deniau, E.; Grandclaudon, P.; Hoarau, C. J. Org.",
        "Chem.1998, 63, 3128\u20133132. doi:10.1021/jo972247t112.Couture, A.; Deniau, E.; Grandclaudon, P.; Rybalko-Rosen,",
        "H.;L\u00e9once, S.; Pfeiffer, B.; Renard, P. Bioorg. Med. Chem. Lett. 2002,12, 3557\u20133559. doi:10.1016/S0960-894X(02)00794-1113.Benesch, L.; Bury, P.; Guillaneux, D.; Houldsworth, S.; Wang,",
        "X.;Snieckus, V. Tetrahedron Lett. 1998, 39, 961\u2013964.doi:10.1016/S0040-4039(97)10670-0 114.Boente, J. M.; Castedo, L.; Dom\u00ednguez, D.; Fari\u00f1a, A.; De Lera, A.",
        "R.;Villaverde, M. C. Tetrahedron Lett. 1984, 25, 889\u2013892.doi:10.1016/S0040-4039(01)80054-X 115.Boente, J. M.; Castedo, L.; De Lera, A. R.; Sa\u00e1, J. M.; Suau,",
        "R.;Vidal, M. C. Tetrahedron Lett. 1984, 25, 1829\u20131830.doi:10.1016/S0040-4039(01)90052-8 116.Tojo, E.; Dominguez, D.; Castedo, L. Phytochemistry 1991,",
        "30,1005\u20131010. doi:10.1016/0031-9422(91)85296-C117.Manske, R. H. F. Can. J. Res., Sect. B 1938, 16, 81\u201390.118.Manske, R. H. F. J. Am. Chem. Soc. 1950, 72,",
        "55\u201359.doi:10.1021/ja01157a017 119.Bhacca, N. S.; Craig, J. C.; Manske, R. H. F.; Roy, S.",
        "K.;Shamma, M.; Slusarchyk, W. A. Tetrahedron 1966, 22, 1467\u20131475.doi:10.1016/S0040-4020(01)99444-X 120.Kametani, T.; Shibuya, S. J. Chem. Soc. 1965,",
        "5565\u20135566.doi:10.1039/jr9650005565 121.Campello, M. J.; Castedo, L.; Dominguez, D.; De Lera, A.",
        "R.;Sa\u00e1, J. M.; Suau, R.; Tojo, E.; Vidal, M. C. Tetrahedron Lett. 1984, 25,5933\u20135936. doi:10.1016/S0040-4039(01)81724-X122.Suau, R.; Rico, R.; L\u00f3pez-Romero, J. M.; N\u00e1jera, F.; Ruiz,",
        "A.;L\u00f3pez, F. J. O. ARKIVOC 2002, No. 5, 62\u201372.doi:10.3998/ark.5550190.0003.508 123.Blaschke, G.; Scriba, G. Phytochemistry 1985, 25,",
        "111\u2013113.doi:10.1016/S0031-9422(00)94512-6 124.Mueller, M. J.; Zenk, M. H. Liebigs Ann. Chem. 1993,",
        "557\u2013563.doi:10.1002/jlac.199319930191 125.De Lera, A. R.; Suau, R.; Castedo, L. J. Heterocycl. Chem. 1987,",
        "24,313\u2013319. doi:10.1002/jhet.5570240204126.Lamas, C.; Castedo, L.; Dominguez, D. Tetrahedron Lett. 1990,",
        "31,6247\u20136248. doi:10.1016/S0040-4039(00)97036-9127.Suau, R.; L\u00f3pezRomero, J. M.; Rico, R. Tetrahedron Lett. 1996,",
        "37,9357\u20139360. doi:10.1016/S0040-4039(97)82963-2128.Moreau, A.; Couture, A.; Deniau, E.; Grandclaudon, P. J. Org.",
        "Chem.2004, 69, 4527\u20134530. doi:10.1021/jo049869g129.Cornforth, J. W. Chem. Br. 1968, 4, 102\u2013106.130.Kamigauchi, T.; Fujiwara, T.; Tani, H.; Kawamura, Y.; Horibe,",
        "I.Sesquiterpene derivatives having antiviral activity. W.O. Patent9711947 A1, April 3, 1997.131.Jarvis, B. B.; Salemme, J.; Morals, A. Nat. Toxins 1995, 3,",
        "10\u201316.doi:10.1002/nt.2620030104 132.Roggo, B. E.; Petersen, F.; Sills, M.; Roesel, J. L.; Moerker,",
        "T.;Peter, H. H. J. Antibiot. 1996, 49, 13\u201319. doi:10.7164/antibiotics.49.13133.Xu, X.; De Guzman, F. S.; Gloer, J. B.; Shearer, C. A. J. Org.",
        "Chem.1992, 57, 6700\u20136703. doi:10.1021/jo00051a006134.Nozawa, Y.; Ito, M.; Sugawara, K.; Hanada, K.; Mizoue, K. J.",
        "Antibiot.1997, 50, 641\u2013645.",
        "doi:10.7164/antibiotics.50.641135.Shinohara, C.; Hasumi, K.; Hatsumi, W.; Endo, A. J. Antibiot.",
        "1996,49, 961\u2013966. doi:10.7164/antibiotics.49.961136.Hinkley, S. F.; Fettinger, J. C.; Dudley, K.; Jarvis, B. B. J.",
        "Antibiot.1999, 52, 988\u2013997. doi:10.7164/antibiotics.52.988137.Kawagishi, H.; Ando, M.; Mizuno, T. Tetrahedron Lett. 1990,",
        "31,373\u2013376. doi:10.1016/S0040-4039(00)94558-1138.Yaoita, Y.; Danbara, K.; Kikuchi, M. Chem. Pharm. Bull. 2005,",
        "53,1202\u20131203. doi:10.1248/cpb.53.1202139.Scherlach, K.; Schuemann, J.; Dahse, H.-M.; Hertweck, C. J.",
        "Antibiot.2010, 63, 375\u2013377. doi:10.1038/ja.2010.46140.Geris, R.; Simpson, T. J. Nat. Prod. Rep. 2009, 26,",
        "1063\u20131094.doi:10.1039/b820413f 141.Minagawa, K.; Kouzuki, S.; Yoshimoto, J.; Kawamura, Y.; Tani,",
        "H.;Iwata, T.; Terui, Y.; Nakai, H.; Yagi, S.; Hattori, N.; Fujiwara, T.;Kamigauchi, T. J. Antibiot. 2002, 55, 155\u2013164.doi:10.7164/antibiotics.55.155 142.Schroeckh, V.; Scherlach, K.; N\u00fctzmann, H. W.; Shelest,",
        "E.;Schmidt-Heck, W.; Schuemann, J.; Martin, K.; Hertweck, C.;Brakhage, A. A. Proc. Natl. Acad. Sci. U. S. A. 2009, 106,14558\u201314563. doi:10.1073/pnas.0901870106143.Kuan, K. K. W.; Pepper, H. P.; Bloch, W. M.; George, J. H. Org.",
        "Lett.2012, 14, 4710\u20134713. doi:10.1021/ol301715u144.Sakurai, J.; Kikuchi, T.; Takahashi, O.; Watanabe, K.; Katoh,",
        "T.Eur. J. Org. Chem. 2011, 2948\u20132957. doi:10.1002/ejoc.201100173145.Nakamura, M.; Ito, Y.; Ogawa, K.; Michisuji, Y.; Sato, S.; Takada,",
        "M.;Hayashi, M.; Yaginuma, S.; Yamamoto, S. J. Antibiot. 1995, 48,1389\u20131395. doi:10.7164/antibiotics.48.1389146.Kende, A. S.; Deng, W.-P.; Zhong, M.; Guo, X.-C. Org. Lett. 2003,",
        "5,1785\u20131788. doi:10.1021/ol030039j147.Li, E.; Jiang, L.; Guo, L.; Zhang, H.; Che, Y. Bioorg. Med.",
        "Chem.2008, 16, 7894\u20137899. doi:10.1016/j.bmc.2008.07.075148.Cueto, M.; Jensen, P. R.; Kauffman, C.; Fenical, W.; Lobkovsky,",
        "E.;Clardy, J. J. Nat. Prod. 2001, 64, 1444\u20131446. doi:10.1021/np0102713149.Slavov, N.; Cvengro\u0161, J.; Neud\u00f6rfl, J. M.; Schmalz,",
        "H.-G.Angew. Chem., Int. Ed. 2010, 49, 7588\u20137591.doi:10.1002/anie.201003755 150.Dalisay, D. S.; Morinaka, B. I.; Skepper, C. K.; Molinski, T.",
        "F.J. Am. Chem. Soc. 2009, 131, 7552\u20137553. doi:10.1021/ja9024929151.Flores, B.; Molinski, T. F. Org. Lett. 2011, 13,",
        "3932\u20133935.doi:10.1021/ol201461n 152.West, L. M.; Northcote, P. T.; Battershill, C. N. J. Org. Chem.",
        "2000,65, 445\u2013449. doi:10.1021/jo991296y153.Bai, R. L.; Paull, K. D.; Herald, C. L.; Malspeis, L.; Pettit, G.",
        "R.;Hamel, E. J. Biol. Chem. 1991, 266, 15882\u201315889.154.Xiao, Q.; Young, K.; Zakarian, A. Org. Lett. 2013, 15,",
        "3314\u20133317.doi:10.1021/ol401354a 155.Alvarez-Mico, X.; Jensen, P. R.; Fenical, W.; Hughes, C. C. Org.",
        "Lett.2013, 15, 988\u2013991. doi:10.1021/ol303374e156.Hughes, C. C.; Prieto-Davo, A.; Jensen, P. R.; Fenical, W. Org.",
        "Lett.2008, 10, 629\u2013631. doi:10.1021/ol702952n157.Matsumoto, N.; Tsuchida, T.; Maruyama, M.; Sawa, R.; Kinoshita,",
        "N.;Homma, Y.; Takahashi, Y.; Iinuma, H.; Naganawa, H.; Sawa, T.;Hamada, M.; Takeuchi, T. J. Antibiot. 1996, 49, 953\u2013954.doi:10.7164/antibiotics.49.953 158.H\u00f6ltzel, A.; Dieter, A.; Schmid, D. G.; Brown, R.; Goodfellow,",
        "M.;Beil, W.; Jung, G.; Fiedler, H.-P. J. Antibiot. 2003, 56, 1058\u20131061.doi:10.7164/antibiotics.56.1058 159.Zhang, X.; Alemany, L. B.; Fiedler, H.-P.; Goodfellow, M.; Parry, R.",
        "J.Antimicrob. Agents Chemother. 2008, 52, 574\u2013585.doi:10.1128/AAC.00717-07",
        "Beilstein J. Org. Chem. 2013, 9,",
        "2048\u20132078.2078",
        "160.Moore, B. S.; Hertweck, C. Nat. Prod. Rep. 2002, 19,",
        "70\u201399.doi:10.1039/b003939j 161.Adachi, S.; Watanabe, K.; Iwata, Y.; Kameda, S.; Miyaoka,",
        "Y.;Onozuka, M.; Mitsui, R.; Saikawa, Y.; Nakata, M.Angew. Chem., Int. Ed. 2013, 52, 2087\u20132091.doi:10.1002/anie.201209205 162.Cox, C. D.; Siu, T.; Danishefsky, S. J. Angew. Chem., Int. Ed.",
        "2003,42, 5625\u20135629. doi:10.1002/anie.200352591163.Siu, T.; Cox, C. D.; Danishefsky, S. J. Angew. Chem., Int. Ed.",
        "2003,42, 5629\u20135634. doi:10.1002/anie.200352592164.Tatsuta, K.; Tanaka, H.; Tsukagoshi, H.; Kashima, T.; Hosokawa,",
        "S.Tetrahedron Lett. 2010, 51, 5546\u20135549.doi:10.1016/j.tetlet.2010.08.035 165.Watanabe, K.; Iwata, Y.; Adachi, S.; Nishikawa, T.; Yoshida,",
        "Y.;Kameda, S.; Ide, M.; Saikawa, Y.; Nakata, M. J. Org. Chem. 2010, 75,5573\u20135579. doi:10.1021/jo100913s166.Kato, K.; Sasaki, T.; Takayama, H.; Akita, H. Tetrahedron 2003,",
        "59,2679\u20132685. doi:10.1016/S0040-4020(03)00300-4167.Wang, F.-P.; Liang, X.-T. C20-diterpenoid alkaloids. The",
        "Alkaloids.Chemistry and Biology; Academic Press, 2002; Vol. 59, pp 1\u2013280.doi:10.1016/S0099-9598(02)59008-8 168.Wang, F.-P.; Chen, Q.-H.; Liu, X.-Y. Nat. Prod. Rep. 2010,",
        "27,529\u2013570. doi:10.1039/b916679c169.Ochiai, E.; Okamoto, T.; Sakai, S.-i.; Saito, A. Yakugaku Zasshi",
        "1956,76, 1414\u20131418.170.Sakai, S.; Yamamoto, I.; Yamaguchi, K.; Takayama, H.; Ito,",
        "M.;Okamoto, T. Chem. Pharm. Bull. 1982, 30, 4579\u20134582.doi:10.1248/cpb.30.4579 171.Jacobs, W. A.; Craig, L. C. J. Biol. Chem. 1942, 143, 605\u2013609.172.Przybylska, M. Can. J. Chem. 1962, 40,",
        "566\u2013568.doi:10.1139/v62-087 173.Suginome, H.; Kakimoto, S.; Sonoda, J.; Noguchi, S. Proc. Jpn.",
        "Acad.1946, 22, 122.174.Pelletier, S. W.; Wright, L. H.; Newton, M. G.; Wright,",
        "H.J. Chem. Soc. D 1970, 98\u201399. doi:10.1039/c29700000098175.Suginome, H.; Shimanouti, F. Justus Liebigs Ann. Chem. 1940,",
        "545,220\u2013228. doi:10.1002/jlac.19405450121176.Okamoto, T. Chem. Pharm. Bull. 1959, 7,",
        "44\u201349.doi:10.1248/cpb.7.44 177.Muratake, H.; Natsume, M. Angew. Chem., Int. Ed. 2004,",
        "43,4646\u20134649. doi:10.1002/anie.200460332178.Peese, K. M.; Gin, D. Y. J. Am. Chem. Soc. 2006, 128,",
        "8734\u20138735.doi:10.1021/ja0625430 179.Peese, K. M.; Gin, D. Y. Chem.\u2013Eur. J. 2008, 14,",
        "1654\u20131665.doi:10.1002/chem.200701290",
        "License and TermsThis is an Open Access article under the terms of theCreative Commons Attribution License(http://creativecommons.org/licenses/by/2.0), whichpermits unrestricted use, distribution, and reproduction inany medium, provided the original work is properly",
        "cited.The license is subject to the Beilstein Journal of OrganicChemistry terms and conditions:(http://www.beilstein-journals.org/bjoc)",
        "The definitive version of this article is the electronic onewhich can be found at:doi:10.3762/bjoc.9.243"
    ]
}